var title_f11_8_11392="Osteomyelitis MRI";
var content_f11_8_11392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image demonstrating osteomyelitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The proximal shaft and metaphysis of the left tibia show an abnormal mottled appearance B) The marrow signal from the left tibia is abnormal. In addition, there is soft tissue inflammation surrounding the left tibia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sheldon L Kaplan, MD. Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11392=[""].join("\n");
var outline_f11_8_11392=null;
var title_f11_8_11393="Pincer nail";
var content_f11_8_11393=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Pincer nail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11393=[""].join("\n");
var outline_f11_8_11393=null;
var title_f11_8_11394="Nummular eczema legs";
var content_f11_8_11394=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nummular dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These coin-shaped scaly lesions show evidence of postinflammatory hyperpigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11394=[""].join("\n");
var outline_f11_8_11394=null;
var title_f11_8_11395="HS Crohns2";
var content_f11_8_11395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's disease mimicking hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11395=[""].join("\n");
var outline_f11_8_11395=null;
var title_f11_8_11396="Fulvestrant: Patient drug information";
var content_f11_8_11396=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fulvestrant: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     see \"Fulvestrant: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/21/2388?source=see_link\">",
"     see \"Fulvestrant: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Faslodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12817149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Faslodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fulvestrant or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help. This most often gets better in a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain and irritation where this drug goes into the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699013",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone, joint, or muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695971",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle once a month.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12502 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11396=[""].join("\n");
var outline_f11_8_11396=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174701\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817149\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011980\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011979\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011984\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011985\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011987\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011982\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011983\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011989\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=related_link\">",
"      Fulvestrant: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/21/2388?source=related_link\">",
"      Fulvestrant: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_8_11397="Nephrology pattern 9 answer";
var content_f11_8_11397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 9 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Membranoproliferative glomerulonephritis. Light micrograph of membranoproliferative glomerulonephritis (MPGN) showing thickening of all capillary walls with double contours (long arrows) and focal areas of cellular proliferation (short arrow). The double-contour or tram-track appearance represents interposition of mesangial cell elements with new glomerular basement membrane synthesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11397=[""].join("\n");
var outline_f11_8_11397=null;
var title_f11_8_11398="Carbinoxamine: Drug information";
var content_f11_8_11398=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbinoxamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/61/4053?source=see_link\">",
"    see \"Carbinoxamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/5/37972?source=see_link\">",
"    see \"Carbinoxamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arbinoxa&trade;;",
"     </li>",
"     <li>",
"      Palgic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F145688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ethanolamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F145679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Allergic rhinitis/urticaria:",
"     </b>",
"     Oral: 4-8 mg 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F145685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/5/37972?source=see_link\">",
"      see \"Carbinoxamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic rhinitis/urticaria:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-5 years: 0.2-0.4 mg/kg/day divided into 3-4 doses",
"     <b>",
"      or",
"     </b>",
"     1-2 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years: 2-4 mg 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution and initiate at lower end of dosing range. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as maleate: 4 mg/5 mL (118 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arbinoxa&trade;: 4 mg/5 mL (480 mL) [contains propylene glycol; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palgic&reg;: 4 mg/5 mL (480 mL) [contains propylene glycol; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arbinoxa&trade;: 4 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palgic&reg;: 4 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13244953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take orally on an empty stomach with water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F145663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seasonal and perennial allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis; mild manifestations of urticaria and angioedema; dermatographism; adjunct therapy for anaphylactic reactions (after acute manifestations controlled)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13931076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F145686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Extrasystoles, hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, confusion, coordination impaired (most frequent), dizziness (most frequent), euphoria, excitability, fatigue, headache, hysteria, insomnia, irritability, nervousness, neuritis, restlessness, sedation (most frequent), seizure, sleepiness (most frequent), vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Early menses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, epigastric distress (most frequent), nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficult urination, urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Labyrinthitis, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchial secretions thickening (most frequent), chest tightness, nasal congestion, nasopharyngeal dryness, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, hypersensitivity reactions (including anaphylactic shock)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F145667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carbinoxamine or any component of the formulation; use with or within 14 days of MAO inhibitor therapy; children &lt;2 years of age; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F145654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with a history of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of this potent anticholinergic agent due to increased risk of confusion, dry mouth, constipation, and other anticholinergic effects; clearance decreases in patients of advanced age (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Fatalities have been reported in children &lt;2 years of age exposed to antihistamines, including medications containing carbinoxamine. Use is contraindicated in children &lt;2 years.  Antihistamines may cause excitation in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F145658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F145670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Maternal antihistamine use has generally not resulted in an increased risk of birth defects; however, information specific for the use of carbinoxamine during pregnancy has not been located. Although antihistamines are recommended for some indications in pregnant women, the use of other agents with specific pregnancy data may be preferred.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F145681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F145671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if carbinoxamine is found in breast milk. Premature infants and newborns have a higher risk of intolerance to antihistamines. Use while breast-feeding is contraindicated by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F145669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Arbinoxa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/5 mL (473 mL): $119.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Carbinoxamine Maleate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/5 mL (118 mL): $20.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Palgic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/5 mL (480 mL): $93.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Arbinoxa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $119.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Carbinoxamine Maleate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $78.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Palgic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $93.51",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Allergefon (FR);",
"     </li>",
"     <li>",
"      Clistin (IN);",
"     </li>",
"     <li>",
"      Histin (TH);",
"     </li>",
"     <li>",
"      Prindex (MX);",
"     </li>",
"     <li>",
"      Santimin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F145653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carbinoxamine competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F145666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of effect: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic (Simons, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (Maurer, 1988)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/8/11398/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maurer H and Pfleger K, \"Screening Procedure for the Detection of Alkanolamine Antihistamines and Their Metabolites in Urine Using Computerized Gas Chromatography-Mass Spectrometry,\"",
"      <i>",
"       J Chromatogr",
"      </i>",
"      , 1988, 428(1):43-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/8/11398/abstract-text/2902103/pubmed\" id=\"2902103\" target=\"_blank\">",
"        2902103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FE, \"Advances in H",
"      <sub>",
"       1",
"      </sub>",
"      -Antihistamines,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(21):2203-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/8/11398/abstract-text/15548781/pubmed\" id=\"15548781\" target=\"_blank\">",
"        15548781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9234 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11398=[""].join("\n");
var outline_f11_8_11398=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145677\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145688\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145679\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145685\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062972\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682483\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682484\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145662\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145651\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244953\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145663\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13931076\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145686\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145667\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145654\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298972\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145658\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145660\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145670\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145681\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145671\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145669\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539826\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145653\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145666\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9234\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9234|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/61/4053?source=related_link\">",
"      Carbinoxamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/5/37972?source=related_link\">",
"      Carbinoxamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_8_11399="Unilateral KW disease Light";
var content_f11_8_11399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unilateral diabetic glomerulosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrographs from a postmortem examination of a diabetic patient with unilateral renal artery stenosis on the right side. Classic Kimmelstiel-Wilson nodules are seen in the glomeruli in the left kidney (left panel); in contrast, the glomeruli are normal in the \"protected\" right kidney (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11399=[""].join("\n");
var outline_f11_8_11399=null;
var title_f11_8_11400="Diagnosis of the carcinoid syndrome and tumor localization";
var content_f11_8_11400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of the carcinoid syndrome and tumor localization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/8/11400/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11400/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11400/contributors\">",
"     Jonathan R Strosberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/8/11400/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11400/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11400/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/8/11400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11400/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/8/11400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;carcinoid&rdquo; is generally applied to neuroendocrine tumors (NETs) originating in the digestive tract, lungs, or rare primary sites such as kidneys or ovaries. Use of the term carcinoid usually implies well-differentiated histology, but the term can be applied to the rare high-grade or poorly differentiated NETs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H440387068#H440387068\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Pathology, tumor classification, and nomenclature'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carcinoid tumors can present in several different ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a result of the carcinoid syndrome: Chronic flushing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea are the typical manifestations of the carcinoid syndrome, which is the result of secretion of serotonin and other vasoactive substances into the systemic circulation. The carcinoid syndrome is primarily associated with metastatic tumors originating in the midgut (distal small intestine and proximal colon). In contrast, hindgut (distal colorectal) and foregut (gastroduodenal, bronchial) carcinoid tumors rarely produce the carcinoid syndrome (",
"      <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"       \"Clinical features of the carcinoid syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link&amp;anchor=H10#H10\">",
"       \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'Presenting signs and symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As a result of tumor growth: Small bowel carcinoid tumors may cause",
"      <span class=\"nowrap\">",
"       chronic/recurrent",
"      </span>",
"      abdominal pain, occasionally leading to bowel obstruction. Metastatic tumors in the liver can cause right upper quadrant pain, hepatomegaly, and early satiety. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical characteristics of carcinoid tumors\", section on 'Jejuno-ileal small bowel tumors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H2#H2\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As an incidental finding: Many carcinoid tumors are discovered during endoscopic or radiographic procedures planned for other purposes; this is especially true of carcinoids of the stomach and rectum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This review will focus on diagnosis of the carcinoid syndrome and",
"    <span class=\"nowrap\">",
"     localization/staging",
"    </span>",
"    of carcinoid tumors. The clinical and pathologic characteristics of carcinoid tumors, treatment and prognosis of carcinoid tumors, and the clinical manifestations and treatment of the carcinoid syndrome are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"       \"Clinical characteristics of carcinoid tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link\">",
"       \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H2#H2\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"       \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"       \"Clinical features of the carcinoid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16888?source=see_link\">",
"       \"Treatment of the carcinoid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOCHEMICAL TESTING FOR THE CARCINOID SYNDROME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4390107\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the carcinoid syndrome is usually considered when a patient has suggestive symptoms such as otherwise unexplained chronic severe diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flushing. Other conditions should be considered in the differential diagnosis, however:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of flushing, for example, includes physiologic events, drugs, and a number of diseases other than the carcinoid syndrome (",
"      <a class=\"graphic graphic_table graphicRef78237 \" href=\"UTD.htm?36/53/37723\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=see_link\">",
"       \"Approach to flushing in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The differential diagnosis for diarrhea is broad. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"       \"Approach to the adult with chronic diarrhea in developed countries\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition to well-differentiated NETs of the gastrointestinal tract that cause the carcinoid syndrome, other well-differentiated NETs arising in the pancreas may cause severe diarrhea including gastrinomas and VIPomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=see_link\">",
"       \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link\">",
"       \"The VIPoma syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical features of the carcinoid syndrome other than flushing and diarrhea are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Urinary excretion of 5-HIAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A useful initial diagnostic test for the carcinoid syndrome is to measure 24-hour urinary excretion of 5-hydroxyindoleacetic acid (HIAA), which is the end product of serotonin metabolism (",
"    <a class=\"graphic graphic_figure graphicRef51368 \" href=\"UTD.htm?12/15/12542\">",
"     figure 1",
"    </a>",
"    ). This test has a sensitivity of over 90 percent and specificity of 90 percent for the carcinoid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/1\">",
"     1",
"    </a>",
"    ]. Sensitivity is lower in patients with carcinoid tumors without the carcinoid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False positive results may be induced by the ingestion of certain drugs and",
"    <span class=\"nowrap\">",
"     tryptophan/serotonin-rich",
"    </span>",
"    foods (",
"    <a class=\"graphic graphic_table graphicRef79968 \" href=\"UTD.htm?7/54/8043\">",
"     table 3",
"    </a>",
"    ). These foods should be avoided for three days prior to urine collection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary excretion of HIAA is generally most useful in patients with primary midgut (jejunoileal, appendiceal, ascending colon) carcinoid tumors, which produce the highest levels of serotonin. Foregut (gastroduodenal, bronchus) and hindgut (transverse, descending and sigmoid colon, rectum, genitourinary) carcinoids only rarely secrete serotonin; they lack the enzyme DOPA decarboxylase and cannot convert 5-hydroxytryptophan (5-HT) to serotonin, and therefore, to 5-HIAA (",
"    <a class=\"graphic graphic_figure graphicRef51368 \" href=\"UTD.htm?12/15/12542\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/4\">",
"     4",
"    </a>",
"    ]; these tumors may produce 5-hydroxytryptophan (and histamine) instead of serotonin. However, there is no commercially available assay for urinary 5-hydroxytyptophan.",
"   </p>",
"   <p>",
"    The normal rate of 5-HIAA excretion ranges from 2 to 8",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (10 to 42",
"    <span class=\"nowrap\">",
"     &micro;mol/day).",
"    </span>",
"    Values of up to 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (157",
"    <span class=\"nowrap\">",
"     &micro;mol/day)",
"    </span>",
"    may be found in patients with malabsorption syndromes such as celiac and Whipple's disease, as well as after the ingestion of large amounts of tryptophan- or serotonin-rich foods (",
"    <a class=\"graphic graphic_table graphicRef79968 \" href=\"UTD.htm?7/54/8043\">",
"     table 3",
"    </a>",
"    ). Although many patients with the carcinoid syndrome have similar modest elevations, some have values for urinary 5-HIAA excretion above 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (523",
"    <span class=\"nowrap\">",
"     &micro;mol/day).",
"    </span>",
"    In one study, for example, urinary 5-HIAA excretion in patients with the carcinoid syndrome ranged from 99 to 2070",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (518 to 10826",
"    <span class=\"nowrap\">",
"     &micro;mol/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should probably avoid intake of tryptophan- and serotonin-rich foods as well as medicines that may cause a false-positive urinary 5-HIAA (",
"    <a class=\"graphic graphic_table graphicRef79968 \" href=\"UTD.htm?7/54/8043\">",
"     table 3",
"    </a>",
"    ) at least 24 hours before and during the 24-hour urine collection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4390319\">",
"    <span class=\"h2\">",
"     Urinary excretion of serotonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of urinary 5-HIAA excretion is generally not useful in foregut (gastroduodenal, bronchial) carcinoids, which often lack aromatic amino acid decarboxylase (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"     table 1",
"    </a>",
"    ). Very rarely, these patients can present with an atypical hormonal syndrome associated with secretion of 5-hydroxytryptophan; however, assays for this metabolite are not available in clinical laboratories in the United States. &nbsp;",
"   </p>",
"   <p>",
"    Measurement of urinary serotonin may be of value in the rare patient with a foregut carcinoid in whom carcinoid syndrome is suspected, since DOPA decarboxylase in the renal parenchyma may convert the 5-hydroxytryptophan to serotonin, leading to high levels of urinary serotonin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chromogranin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromogranins (designated as A, B, and C) are proteins that are stored and released with peptides and amines in a variety of neuroendocrine tissues. Well-differentiated neuroendocrine tumors, including carcinoids, are associated with elevated blood concentrations of chromogranins, which increase with larger tumor burden [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/3,6-8\">",
"     3,6-8",
"    </a>",
"    ]. Chromogranins B and C are less sensitive indicators of neuroendocrine tumors as compared to chromogranin A (CgA) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Levels of CgA secretion vary on a day by day basis in healthy subjects and those with NETs. Food intake also increases CgA levels [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In general, CgA is a sensitive but nonspecific marker for neuroendocrine tumors such as carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the sensitivity and specificity of CgA for the diagnosis of NETs depends on the cutoff value [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. This was illustrated in a series that compared plasma CgA levels in 238 patients with well-differentiated neuroendocrine tumors, 42 with chronic atrophic gastritis, and 48 healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/7\">",
"     7",
"    </a>",
"    ]. Using the DAKO ELISA kit, the best cutoff range between participants without neoplasia and those with neuroendocrine tumors was 31 to 32",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    (sensitivity and specificity of 75 and 84 percent, respectively). When specificity was set at 95 percent, with a cutoff of 84 to 87",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    sensitivity was only 55 percent. This assay, which measures CgA concentration in",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    is not usually used in the United States; there is a lack of international standardization that makes it difficult to extrapolate these values to other CgA assays [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/13\">",
"     13",
"    </a>",
"    ]. False positive elevations of CgA can be present in a number of other conditions (",
"    <a class=\"graphic graphic_table graphicRef73287 \" href=\"UTD.htm?40/9/41116\">",
"     table 4",
"    </a>",
"    ). They are especially common in patients who are taking a proton pump inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Due to its relatively low specificity, we do not recommend the use of CgA alone as a screening test for diagnosis of a carcinoid tumor or the carcinoid syndrome. When evaluating patients for a possible carcinoid syndrome, both plasma CgA and urinary 5-HIAA are useful, although 5-HIAA is of greater specificity. CgA is an appropriate tumor marker for patients with an established diagnosis in order to assess disease progression, response to therapy or recurrence after surgical resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H10#H10\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Chromogranin A'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Blood serotonin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various serotonin assays have been described in the literature including whole blood serotonin, platelet-rich plasma serotonin and platelet poor plasma serotonin assays. However, the sensitivities and specificities of these assays have not been well established. &nbsp;In one report, the mean fasting blood serotonin concentration in normal subjects ranged from 71 to 310",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (0.4 to 1.8",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    Ten patients with the carcinoid syndrome had markedly elevated values, from 790 to 4500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (4.5 to 25.5",
"    <span class=\"nowrap\">",
"     &micro;mol/L);",
"    </span>",
"    of these, two had normal urinary 5-HIAA excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/16\">",
"     16",
"    </a>",
"    ]. However, false positive serotonin tests may occur due release of platelet serotonin as well as by ingestion of",
"    <span class=\"nowrap\">",
"     tryptophan/serotonin-rich",
"    </span>",
"    foods [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/17\">",
"     17",
"    </a>",
"    ]. Consequently, we do not recommend measurement of blood serotonin levels as a standard diagnostic test for the carcinoid syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TUMOR LOCALIZATION AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carcinoid syndrome is primarily associated with metastatic carcinoid tumors that originate in the small intestine or proximal colon. Vasoactive peptides that are produced by localized intestinal carcinoid tumors are inactivated in the portal circulation and thus do not result in the carcinoid syndrome. Imaging studies should therefore focus on the abdomen and pelvis. CT, MRI, and somatostatin receptor scintigraphy (SRS, OctreoScans) are the primary imaging modalities used to identify metastatic carcinoid tumors. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31868282\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scans are noninvasive and readily available. Helical (spiral) multiphasic contrast-enhanced CT is recommended for evaluation of patients with carcinoid tumors, with the exception of type I and 2 gastric carcinoids unless they are large (&gt;2 cm) or invasive [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18950?source=see_link&amp;anchor=H3#H3\">",
"     \"Computed tomography of the hepatobiliary tract\", section on 'Contrast material'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18950?source=see_link&amp;anchor=H5#H5\">",
"     \"Computed tomography of the hepatobiliary tract\", section on 'Helical (spiral) CT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Foregut tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most carcinoid tumors are highly vascular, and liver metastases may appear isodense with the liver on a noncontrasted study. Following the injection of intravenous (IV) contrast, carcinoids often enhance with iodinated contrast during the early arterial phase (approximately 20 seconds after contrast injection), with washout during the portal venous imaging phase (approximately 70 seconds after contrast injection) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, arterial phase and portal venous phase sequences can be used to maximize the conspicuity of liver metastases compared to the surrounding normal liver parenchyma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52935 \" href=\"UTD.htm?16/0/16392\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Carcinoid tumors originating in the small intestine often produce mesenteric masses with dense desmoplastic fibrosis, either due to direct extension of primary tumors into the mesentery, or due to mesenteric lymph node metastases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78186 \" href=\"UTD.htm?42/57/43921\">",
"     image 2",
"    </a>",
"    ). CT scans are ideal for identification of these tumors, which are often located in the root of the mesentery and are characterized by a circumferential pattern of fibrosis which tethers surrounding small bowel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31868289\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI may represent the most sensitive method for detection of liver metastases. In one study of 64 patients with metastatic gastrointestinal neuroendocrine tumors, multiphasic MRI detected more hepatic lesions than either CT or somatostatin receptor scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/20\">",
"     20",
"    </a>",
"    ]. As a result of this greater sensitivity for liver metastases, some physicians prefer MRI over CT for assessing the status of the liver in patients with carcinoid tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/21\">",
"     21",
"    </a>",
"    ]. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H262522974#H262522974\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Cross-sectional imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with CT scans, early arterial phase imaging following the injection of contrast is critical for the detection of small hypervascular liver metastases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52935 \" href=\"UTD.htm?16/0/16392\">",
"     image 1",
"    </a>",
"    ). In a study of 37 patients with liver metastases from gastroenteropancreatic NETs, the most sensitive sequences for detection of liver metastases were hepatic arterial phase and fast spin-echo T2-weighed images [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31868296\">",
"    <span class=\"h2\">",
"     Somatostatin-receptor scintigraphy (OctreoScan)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many carcinoid tumors express high levels of somatostatin receptors and can therefore be imaged with a radiolabeled form of the somatostatin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (111-indium pentetreotide) using somatostatin receptor scintigraphy (SRS, OctreoScan). This technique has the advantage of instantaneous whole body scanning, which also allows detection of metastases outside of the abdominal region. Poorly differentiated neuroendocrine tumors express low somatostatin-receptor levels and are unlikely to be detected on OctreoScan imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accuracy of SRS has improved with the addition of single photon emission computed tomography (SPECT) to planar imaging, since SPECT permits more accurate differentiation between areas of pathologic and physiologic uptake in the abdomen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81388 \" href=\"UTD.htm?15/21/15703\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72923 \" href=\"UTD.htm?43/32/44558\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62072 \" href=\"UTD.htm?41/44/42703\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a report describing 72 patients with gastroenteropancreatic neuroendocrine tumors (ie, carcinoid, pancreatic neuroendocrine (islet cell) tumor, or other) who were examined with",
"    <span class=\"nowrap\">",
"     SPECT/CT",
"    </span>",
"    hybrid imaging, localization was improved in 23 of 44 SRS-positive studies, and the test affected clinical management in 10 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In older studies, the sensitivity of SRS compared favorably with other imaging modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/26\">",
"     26",
"    </a>",
"    ]. However, technological advancements in CT and MRI scans over the past several decades have led some to question whether SRS is still a necessary component of the staging workup for carcinoid and other neuroendocrine tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 121 patients with a gastroenteropancreatic neuroendocrine tumor, 107 of whom had metastatic disease, multiphase contrast-enhanced CT or MRI detected more pathologic lesions than did SPECT-SRS [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/27\">",
"       27",
"      </a>",
"      ]. Of the 107 patients with metastatic disease that was demonstrated by CT or MRI, only 85 (79 percent) had abnormal findings on SRS that correlated with the abnormalities on cross-sectional imaging. Furthermore, none of the 107 patients had soft tissue abnormalities or primary tumors identified by SPECT-SRS that were not also seen on cross-sectional imaging. SPECT-SRS did identify clinically unsuspected bone metastases that were not identified on CT or MRI.",
"      <br/>",
"      <br/>",
"      The authors concluded that the routine use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      scanning as an adjunct for tumor staging was not justified unless the finding of asymptomatic bone lesions would change patient management and the treatment plan.",
"     </li>",
"     <li>",
"      In another study of 37 patients with a neuroendocrine tumor, MRI, and CT were substantially superior to SRS for detection of liver metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/22\">",
"       22",
"      </a>",
"      ]. The sensitivity of OctreoScans was found to be particularly poor (&lt;35 percent) for lesions smaller than 1.5 cm in diameter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in our view and that of others, including the European Neuroendocrine Tumor Society (ENETs) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/28\">",
"     28",
"    </a>",
"    ], SRS is complementary to cross sectional imaging in the evaluation of a patient with carcinoid syndrome. In addition to localization of extraabdominal disease sites, SRS offers functional information on levels of somatostatin-receptor expression; this can aid in the selection of appropriate candidates with advanced disease for somatostatin-based therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In centers that perform peptide receptor radioligand therapy with radiolabeled somatostatin analogs such as 90-Y-DOTA tyr3-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      (",
"      <sup>",
"       90",
"      </sup>",
"      Y-edotreotide) or 177-Lu-DOTA, Tyr",
"      <sup>",
"       3",
"      </sup>",
"      -octreotate (177-Lu-DOTATOC), SRS is an essential component of workup since levels of radiotracer uptake predict response to treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11400/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949126#H190949126\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Radiolabeled somatostatin analogs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is less clear whether the level of radiotracer uptake predicts response to the conventional, non-radiolabeled somatostatin analogs",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"       lanreotide",
"      </a>",
"      . Some physicians advocate baseline SRS prior to treatment with a somatostatin analog; however, patients with hormonal syndromes and a negative SRS may respond to therapy with a somatostatin receptor analog. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948928#H190948928\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Octreotide and other somatostatin analogs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31868311\">",
"    <span class=\"h2\">",
"     Functional PET imaging techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not yet clinically available, several positron emission tomography (PET) tracers for functional imaging have emerged (18-F-dihydroxy-phenyl-alanine [18F-DOPA], 11-C-5-hydroxytryptophan [11-C-5-HTP]), and 68-Ga-DOTA- D-Phe",
"    <sup>",
"     1",
"    </sup>",
"    -Tyr",
"    <sup>",
"     3",
"    </sup>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    (68-Ga-DOTATOC), which, in combination with high resolution PET integrated with CT, hold promise for improved detection and staging of NETs in the future. These novel PET modalities offer higher spatial resolution than conventional somatostatin receptor scintigraphy (SRS) and are associated with improved sensitivity for detection of small lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81388 \" href=\"UTD.htm?15/21/15703\">",
"     image 3",
"    </a>",
"    ). This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H7#H7\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Other functional imaging methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432325\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper and lower endoscopy (with attention to the terminal ileum) should be performed for the evaluation of metastatic carcinoid with an unknown primary site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bronchial carcinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H262522974#H262522974\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Cross-sectional imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT scans and SRS can be used to localize bronchial carcinoid tumors. These tumors tend to be centrally located endobronchial lesions; however, approximately 20 percent arise peripherally and present as a well circumscribed solitary pulmonary nodule (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61692 \" href=\"UTD.htm?29/16/29967\">",
"     image 5",
"    </a>",
"    ). Bronchial carcinoids can present with atypical carcinoid syndrome, characterized by severe and prolonged flushes, hemoptysis, or rarely signs of left-sided heart failure due to valve disease, even in the absence of hepatic metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of the carcinoid syndrome may be suspected when a patient has suggestive symptoms such as otherwise unexplained diarrhea or flushing. However other diagnoses must be considered. The differential diagnosis of flushing, for example, includes physiologic events, drugs, and a number of diseases other than the carcinoid syndrome (",
"      <a class=\"graphic graphic_table graphicRef78237 \" href=\"UTD.htm?36/53/37723\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"       \"Clinical features of the carcinoid syndrome\"",
"      </a>",
"      .) Moreover, other neuroendocrine tumor types can cause severe chronic diarrhea. (See",
"      <a class=\"local\" href=\"#H4390107\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most useful initial diagnostic test for the carcinoid syndrome is to measure 24-hour urinary excretion of 5-hydroxyindoleacetic acid (HIAA), which is the end product of serotonin metabolism (",
"      <a class=\"graphic graphic_figure graphicRef51368 \" href=\"UTD.htm?12/15/12542\">",
"       figure 1",
"      </a>",
"      ). Depending on the cutoff value used, this test has a high sensitivity and high specificity for carcinoid syndrome but requires strict avoidance of foods containing serotonin and tryptophan as well as certain drugs for three days prior to the urine collection (",
"      <a class=\"graphic graphic_table graphicRef79968 \" href=\"UTD.htm?7/54/8043\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Urinary excretion of 5-HIAA'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Measurement of urinary 5-HIAA excretion is generally not useful in foregut (gastroduodenal, bronchial) carcinoids, which often lack aromatic amino acid decarboxylase. In this setting, we would pursue imaging studies to search for a carcinoid tumor.",
"      <br/>",
"      <br/>",
"      Due to its relatively low specificity, we do not recommend the use of serum chromogranin A (CgA) as a screening test for diagnosis of the carcinoid syndrome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chromogranin concentration'",
"      </a>",
"      above.) However, a normal CgA would mitigate against the presence of a carcinoid tumor.",
"     </li>",
"     <li>",
"      Once the biochemical diagnosis of the carcinoid syndrome is confirmed, usually by an elevated 24-hour excretion of 5 HIAA, the tumor must be localized. Two techniques, abdominal computed tomography (CT) and somatostatin receptor scintigraphy (SRS), have a complementary role in tumor localization. For diagnostic workup of carcinoid syndrome, we generally perform helical, contrast enhanced, triple-phase CT scans of the abdomen and pelvis. (See",
"      <a class=\"local\" href=\"#H31868282\">",
"       'Computed tomography'",
"      </a>",
"      above.) SRS offers whole-body imaging and functional information regarding tumoral expression of somatostatin receptors. (See",
"      <a class=\"local\" href=\"#H31868296\">",
"       'Somatostatin-receptor scintigraphy (OctreoScan)'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Contrast-enhanced MRIs of the abdomen and pelvis are an acceptable alternative and are preferred by some physicians because of their greater sensitivity for liver metastases. (See",
"      <a class=\"local\" href=\"#H31868289\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/1\">",
"      Sj&ouml;blom SM. Clinical presentation and prognosis of gastrointestinal carcinoid tumours. Scand J Gastroenterol 1988; 23:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/2\">",
"      O'Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/3\">",
"      Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/4\">",
"      Feldman JM. Carcinoid tumors and syndrome. Semin Oncol 1987; 14:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/5\">",
"      Feldman JM. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem 1986; 32:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/6\">",
"      Eriksson B, Arnberg H, Oberg K, et al. A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. Acta Endocrinol (Copenh) 1990; 122:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/7\">",
"      Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/8\">",
"      Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/9\">",
"      Stridsberg M, Oberg K, Li Q, et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/10\">",
"      Granberg D, Stridsberg M, Seensalu R, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999; 84:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/11\">",
"      Fossmark R, Jianu CS, Martinsen TC, et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008; 43:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/12\">",
"      Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 2007; 14:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/13\">",
"      Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/14\">",
"      Pregun I, Hersz&eacute;nyi L, Juh&aacute;sz M, et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/15\">",
"      Korse CM, Muller M, Taal BG. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer 2011; 105:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/16\">",
"      Richter G, St&ouml;ckmann F, Conlon JM, Creutzfeldt W. Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors. Gastroenterology 1986; 91:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/17\">",
"      Allen KR, Degg TJ, Anthoney DA, Fitzroy-Smith D. Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples. Ann Clin Biochem 2007; 44:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/18\">",
"      Sundin A, Vullierme MP, Kaltsas G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/19\">",
"      Paulson EK, McDermott VG, Keogan MT, et al. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 1998; 206:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/20\">",
"      Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/21\">",
"      Pisegna JR, Doppman JL, Norton JA, et al. Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/22\">",
"      Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003; 180:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/23\">",
"      Strosberg J, Nasir A, Coppola D, et al. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009; 40:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/24\">",
"      Schillaci O, Corleto VD, Annibale B, et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2:S186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/25\">",
"      Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003; 59:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/26\">",
"      Schirmer WJ, Melvin WS, Rush RM, et al. Indium-111-pentetreotide scanning versus conventional imaging techniques for the localization of gastrinoma. Surgery 1995; 118:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/27\">",
"      Reidy-Lagunes DL, Gollub MJ, Saltz LB. Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? J Clin Oncol 2011; 29:e74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/28\">",
"      Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11400/abstract/29\">",
"      Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26:2124.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2622 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.102.30.19-B4B63FB7F5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11400=[""].join("\n");
var outline_f11_8_11400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOCHEMICAL TESTING FOR THE CARCINOID SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4390107\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Urinary excretion of 5-HIAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4390319\">",
"      Urinary excretion of serotonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chromogranin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Blood serotonin concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TUMOR LOCALIZATION AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31868282\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31868289\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31868296\">",
"      Somatostatin-receptor scintigraphy (OctreoScan)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31868311\">",
"      Functional PET imaging techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432325\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bronchial carcinoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2622\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2622|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/0/16392\" title=\"diagnostic image 1\">",
"      CT neuroendocrine tumor liver metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/57/43921\" title=\"diagnostic image 2\">",
"      Malignant carcinoid ileum CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/21/15703\" title=\"diagnostic image 3\">",
"      Functional PET imaging for metastatic GI neuroendocrine tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/44/42703\" title=\"diagnostic image 4\">",
"      Primary ileal NET somatostatin receptor scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/16/29967\" title=\"diagnostic image 5\">",
"      Carcinoid tumor CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2622|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/15/12542\" title=\"figure 1\">",
"      Tryptophan and serotonin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2622|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/32/44558\" title=\"picture 1\">",
"      Liver metastases on somatostatin receptor scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2622|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/7/17531\" title=\"table 1\">",
"      Characteristics of carcinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/53/37723\" title=\"table 2\">",
"      Causes of flushing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/54/8043\" title=\"table 3\">",
"      Interference with 5 HIAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/9/41116\" title=\"table 4\">",
"      Conditions associated with elevated chromogranin A",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=related_link\">",
"      Approach to flushing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18950?source=related_link\">",
"      Computed tomography of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=related_link\">",
"      Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16888?source=related_link\">",
"      Treatment of the carcinoid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_8_11401="Nutritional demands and enteral formulas for moderate to severe burn patients";
var content_f11_8_11401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nutritional demands and enteral formulas for moderate to severe burn patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/8/11401/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11401/contributors\">",
"     Amalia Cochran, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/8/11401/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11401/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/8/11401/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11401/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/8/11401/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional support represents one of the most important cornerstones in the management of patients with a moderate to severe burn injury. This topic covers determination of caloric requirements and selection of enteral formulas. The target goal of avoiding the extremes of starvation and overfeeding is defined by estimating energy requirements, and is subject to continued monitoring and revision based upon the metabolic characteristics of patients and their tolerance of enteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Information on patient selection and timing of nutritional support and evaluating nutritional support is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=see_link\">",
"     \"Overview of nutritional support for moderate to severe burn patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15716?source=see_link\">",
"     \"Evaluating nutritional support for moderate to severe burn patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINING CALORIC REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fundamental goal in nutritional support is to meet but not exceed the nutritional requirements of patients with moderate to severe burns. Assessment of nutritional support falls into two distinct categories: the initial requirements and the ongoing requirements. The assessment of caloric demands within the first 24 hours generates an initial goal so that nutritional support can be initiated. However, the most critical component is to make adjustments for the ongoing needs during what is often a prolonged recovery associated with a prolonged course of hypermetabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial nutritional support goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The target goal of avoiding the extremes of starvation and overfeeding is determined by estimating energy requirements, and is subject to revision based upon the metabolic characteristics of patients and their tolerance of enteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Initial estimates of energy expenditure in burn patients provides a particular challenge because of the variability of the hypermetabolic response and the factors that result in heterogeneity of energy expenditure in burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Calculating energy requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of the energy requirements represents a composite of the following factors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basal metabolic rate",
"     </li>",
"     <li>",
"      Hypermetabolism",
"     </li>",
"     <li>",
"      Percent of total body surface area (TBSA) burned",
"     </li>",
"     <li>",
"      Ventilatory support",
"     </li>",
"     <li>",
"      Infections",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Multiple organ failure",
"     </li>",
"     <li>",
"      Level of physical activity",
"     </li>",
"     <li>",
"      Thermic effect of food",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assessment of the energy requirements is an ongoing process and modified according to the progress of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/5\">",
"     5",
"    </a>",
"    ]. No single formula accurately assesses the true caloric needs and continued vigilance is required to avoid complications associated with either overfeeding or underfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many mathematical equations have been devised to estimate the caloric requirements of the burn patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Avoidance of overfeeding minimizes the risks of hyperglycemia, fat accretion and infections [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ]. However, most of the formulas overestimate the amount of calories required in burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Indirect calorimetry is the most accurate tool to assess caloric requirements, but requires specialized equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. One of the first formulas, the Curreri formula, is used worldwide to estimate the caloric requirement in adult and pediatric burn patients. The Galveston Shriners Burns Institute has also developed formulas to be used in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Indirect calorimetry estimation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect calorimetry (IDC) has been more beneficial for estimating caloric requirements of the burn patient than the predictive Curreri formula; however, the equipment necessary to perform the tests is not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/8,14,15\">",
"     8,14,15",
"    </a>",
"    ]. Considered to be the \"gold standard\" for assessing energy expenditure, the IDC method uses respiratory gas exchange to estimate fuel consumption. Results of IDC are affected by oxygen therapy, hemodynamic instability, fever, and any ongoing procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Harris-Benedict equation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Harris-Benedict equation and the Curreri formula are the most widely used algebraic formulas for the estimation of caloric requirements in adult burn patients. The Harris-Benedict equation is an accepted standard for estimating basal energy expenditure (BEE). For burn patients, the BEE is multiplied by an arbitrary activity or stress factor of 1.2 to 2.0. For all but the most extensive burn injuries, the acceptable stress factor is between 1.2 and 1.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. While useful for initial estimate of energy demands, the equation overestimates the caloric requirements of burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The equation used for men is:",
"      <br/>",
"      <br/>",
"      BEE (kcal per day) = 66.5 + (13.8) Weight in Kg + (5) Height in cm - (6.76) Age in years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The equation used for women is:",
"      <br/>",
"      <br/>",
"      BEE (kcal per day) = 655 + (9.6) Weight in Kg + (1.85) Height in cm - (4.68) Age in years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Curreri formula",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Curreri formula provides for maintenance needs plus the additional caloric requirements for the burn injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/5,17-19\">",
"     5,17-19",
"    </a>",
"    ]. The two factors used in this formula, percent TBSA and body weight prior to the burn, estimate the energy requirements by linear regression analysis based on the number of calories required to prevent weight loss during the first few weeks postburn [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/8\">",
"     8",
"    </a>",
"    ]. This formula was based on nine adult patients. It does not take into account gender, age, activity or ventilatory status.",
"   </p>",
"   <p>",
"    While the Curreri formula has been accepted worldwide, it overestimates the caloric needs of burn patients when compared to metabolic expenditure requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/5,8,20\">",
"     5,8,20",
"    </a>",
"    ]. The overestimation may be related to the changes in burn care since the formula was developed. Early wound closure, higher ambient temperature, improvements in infection control, and pain management all reduce the hypermetabolic response to the burn injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Curreri formula for adults age 16 to 59 years is:",
"      <br/>",
"      <br/>",
"      Caloric requirement (kcal per day) = 25",
"      <span class=\"nowrap\">",
"       kcal/kg/day",
"      </span>",
"      + 40",
"      <span class=\"nowrap\">",
"       kcal/percent",
"      </span>",
"      TBSA",
"      <span class=\"nowrap\">",
"       burned/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Curreri formula for adults over age 60 years is:",
"      <br/>",
"      <br/>",
"      Caloric requirement (kcal per day) = 25",
"      <span class=\"nowrap\">",
"       kcal/kg/day",
"      </span>",
"      + 65",
"      <span class=\"nowrap\">",
"       kcal/percent",
"      </span>",
"      TBSA",
"      <span class=\"nowrap\">",
"       burned/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cunningham prediction equation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cunningham prediction equation uses fat free body mass (FFM) in calculating resting energy expenditure (REE) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Permissive underfeeding for obese patients'",
"    </a>",
"    below.) FFM is calculated by: (1) defining the ideal body mass index as 25, (2) back-calculating ideal weight using the patient's height, (3) defining excess weight as the difference between actual weight and ideal weight. An injury factor of 20 percent is used to calculate the increase in energy expenditure in burned patients. FFM is defined as the sum of the ideal weight plus 25 percent of the excess weight.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      REE",
"      <span class=\"nowrap\">",
"       (kcal/day)",
"      </span>",
"      = 370 + 21.6(FFM).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Toronto formula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another complicated formula, the Toronto formula is used to predict the energy requirements of the ventilated burn patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/5,10,23\">",
"     5,10,23",
"    </a>",
"    ]. The formula requires an ongoing collection of patient data. The formula was developed by using multiple regression analysis to determine the factors that best approximated the measured energy expenditure (MEE). The factors included in the equation are: a factor of activity, total body surface area (TBSA); caloric intake (CI); estimated basal energy expenditure calculated by the Harris-Benedict formula (EEBE), and number of post-burn days (PBD).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MEE (",
"      <span class=\"nowrap\">",
"       kcal/day)",
"      </span>",
"      = -4343 + (10.5 x percent TBSA) + (0.23 x CI) + (0.84 x EBEE) + (114 x Temp (degree C)) - (4.5 x PBD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pediatric formulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently used calculation schemes for caloric requirements in pediatric burn patients include Recommended Dietary",
"    <span class=\"nowrap\">",
"     Allowances/Recommended",
"    </span>",
"    Daily Intake",
"    <span class=\"nowrap\">",
"     (RDA/",
"    </span>",
"    RDI), Curreri Jr., and the Galveston formulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     RDA/RDI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Recommended Dietary Allowance or RDA (sometimes referred to as Recommended Daily Allowance) is defined as the average daily dietary intake level that is sufficient to meet the nutrient requirements of nearly all (approximately 98 percent) healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/24\">",
"     24",
"    </a>",
"    ]. Reference Daily Intake (or Recommended Daily Intake) (RDI) is the daily dietary intake level of a nutrient which was considered at the time they were defined to be sufficient to meet the requirements of nearly all (97&ndash;98 percent) healthy individuals. RDIs are based on the older RDA recommendations. Use of this scheme prevents overfeeding found with the older formulas (eg, Curreri and Galveston).",
"   </p>",
"   <p>",
"    The caloric requirements for adults based on the RDI recommendations is: RDI (kcal per day) = 37 (weight in kilograms). The caloric requirements for children with a 40 percent TBSA are calculated using a formula that contains a modifier based on age multiplied by weight in kilograms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/5\">",
"     5",
"    </a>",
"    ]. (",
"    <a class=\"graphic graphic_table graphicRef57274 \" href=\"UTD.htm?28/7/28795\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Curreri Junior",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Curreri Junior formula is based upon adult Curreri calculations with modification for age and RDA. It, too, overestimates the caloric requirements of burn patients. The formulas to calculate caloric requirements for children are based on age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/5\">",
"     5",
"    </a>",
"    ]. (",
"    <a class=\"graphic graphic_table graphicRef78277 \" href=\"UTD.htm?3/62/4075\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Galveston Shriners Burns Institute",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Galveston Shriners Burns Institute formulas are frequently used to estimate energy demands for pediatric burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/25\">",
"     25",
"    </a>",
"    ]. These formulas are a reasonable alternative to the",
"    <span class=\"nowrap\">",
"     RDA/RDI",
"    </span>",
"    formulas. The formula for children under one year of age was derived from a multivariate regression analysis of 30 children with at least a 25 percent TBSA burn (",
"    <a class=\"graphic graphic_table graphicRef57274 \" href=\"UTD.htm?28/7/28795\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/26\">",
"     26",
"    </a>",
"    ]. The formulas for children over one year of age were derived by direct observations of the actual caloric intake required to maintain weight in 121 pediatric patients with burns greater than 30 percent total body surface area [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/27\">",
"     27",
"    </a>",
"    ]. The formulas are based on age and total body surface area burned (",
"    <a class=\"graphic graphic_table graphicRef69059 \" href=\"UTD.htm?10/22/10603\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Permissive underfeeding for obese patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lean body mass (LBM) is the site of metabolism, and LBM is just slightly greater in obese compared to normal weight individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/21\">",
"     21",
"    </a>",
"    ]. Permissive underfeeding, which uses ideal body weight to estimate caloric need, counters hyperglycemia and weight gain that result from overfeeding critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/28\">",
"     28",
"    </a>",
"    ]. Permissive underfeeding is a reasonable strategy in obese critically ill patients who have less metabolic derangement and less need for short-term support than burn patients. Permissive underfeeding relies on fat oxidation to mobilize peripheral stores as an energy source, a process that is impaired in patients with a significant burn injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review of 28 obese burn and trauma patients found that the Harris-Benedict equation and the Cunningham prediction equation under-predicted the resting energy expenditure (REE) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Calculating energy requirements'",
"    </a>",
"    above.) When an injury factor of 20 percent is included in the calculations, the Cunningham equation was the most accurate for predicting REE. The Cunningham equation potentially alleviates overfeeding in obese burn patients by using lean body weight, rather than current weight [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NUTRIENT COMPOSITION FOR ENTERAL FORMULAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections describe the recommended macronutrients and micronutrients in the enteral formulas used for moderate to severe burn injury patients. We recommend delivery of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1.5 to 2.0 grams",
"      <span class=\"nowrap\">",
"       protein/kg/day",
"      </span>",
"     </li>",
"     <li>",
"      5 to 7",
"      <span class=\"nowrap\">",
"       mg/kg/min",
"      </span>",
"      of glucose per day representing approximately 50 percent of total calories",
"     </li>",
"     <li>",
"      Fewer than 15 percent of nonprotein calories from fat sources",
"     </li>",
"     <li>",
"      Vitamins A, C and D in standard multivitamin formulations",
"     </li>",
"     <li>",
"      Trace minerals (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      , zinc and copper) in standard formulations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Macronutrients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to establishing initial caloric energy requirements, determination of the appropriate composition of protein, carbohydrates, and fats for a nutrition support regimen is an early priority. Carbohydrates stimulate protein synthesis and limit loss of lean body mass, thereby making a high-carbohydrate diet preferable in patients who have sustained a moderate to severe burn injury.",
"   </p>",
"   <p>",
"    This was illustrated in a muscle protein kinetic trial performed on 14 severely burned children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/32\">",
"     32",
"    </a>",
"    ]. Subjects randomly received either a high-carbohydrate enteral diet (3 percent fat, 82 percent carbohydrate, 15 percent protein) or a high-fat enteral diet (44 percent fat, 42 percent carbohydrates, 14 percent protein) for one week, and then crossed over to the other diet for a second week. Patients treated with a high-carbohydrate diet had significantly decreased muscle protein degradation and significantly increased endogenous insulin concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of nutrition support with protein of 1.5 to 2.0",
"    <span class=\"nowrap\">",
"     grams/kg/day,",
"    </span>",
"    approximately 20 to 25 percent of calories per day, will provide a balanced between synthesis and breakdown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urea production, and therefore protein oxidation, in burned patients occurs at a rate approximately twice that of healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/33\">",
"     33",
"    </a>",
"    ]. Studies of protein intake in burns have examined intake levels of 1.5",
"    <span class=\"nowrap\">",
"     grams/kg/day",
"    </span>",
"    and greater to determine optimal quantities. Delivery of greater than 1.5",
"    <span class=\"nowrap\">",
"     grams/kg/day",
"    </span>",
"    in adult burns does not improve protein synthesis but does enhance maintenance of an isonitrogenous state [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sufficient protein is a priority in the nutrition support of burn patients to minimize the impact of the catabolic response to burn injury and to assist in the protein synthesis required for wound healing and immune function. It has been estimated that healthy individuals synthesize protein at a rate of approximately 4",
"    <span class=\"nowrap\">",
"     grams/kg/day,",
"    </span>",
"    in contrast to the 7.6",
"    <span class=\"nowrap\">",
"     grams/kg/day",
"    </span>",
"    rate of protein synthesis that has been estimated in burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose is the preferred substrate for wound healing and should be the major source of calories in burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Ideally, carbohydrates administered for burn nutrition support should consist of 5 to 7",
"    <span class=\"nowrap\">",
"     mg/kg/min",
"    </span>",
"    of glucose and represent approximately 50 percent of total calories provided [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from an observational study suggested that there is a maximal rate of glucose infusion beyond which physiologically significant increases in protein synthesis and direct oxidation of glucose cannot be expected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/38\">",
"     38",
"    </a>",
"    ]. There also appeared to be a physiological cost of exceeding the optimal glucose infusion rate, as indicated by increased rates of CO2 production during infusion as well as large fat deposits in the liver at autopsy in patients infused with large amounts of glucose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipids are an important dietary component as they contain the essential fatty acids, but should comprise no more than 15 percent of total calories. Lipids serve as carriers of lipid-soluble vitamins. Following a moderate to severe burn injury, oxidation of free fatty acids occurs at a rate more than double that of healthy people [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/33\">",
"     33",
"    </a>",
"    ]. This enhanced process of lipolysis allows for excess exogenous fat to heighten recycling of free fatty acids and may result in increased fat storage.",
"   </p>",
"   <p>",
"    Nutritional support with more than 15 percent of calories from lipid has been demonstrated to impair immunologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/37,39-42\">",
"     37,39-42",
"    </a>",
"    ]. In a randomized clinical trial, 43 moderate to severe burn patients were assigned to one of the following groups: high-fat solution (35 percent of total calories as fat), low-fat solution (15 percent fat), low-fat solution with fish oil (15 percent fat), administered for 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/39\">",
"     39",
"    </a>",
"    ]. Compared with the high-fat control group, groups on low-fat support had significantly fewer cases of pneumonia (3 out of 24 versus 7 out of 13), and a significantly shorter time to healing (1.2 versus 1.8",
"    <span class=\"nowrap\">",
"     days/percent",
"    </span>",
"    total body surface area burned). There was no difference in nitrogen balance between the high-fat and low-fat groups, and 3-methylhistidine excretion was higher and serum free cortisol was lower in the low-fat groups. Fish oil did not seem to add clinical benefit to low-fat solutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Micronutrients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintaining appropriate levels of trace elements in moderate to severe burn patients is difficult due to exudative losses consequent to loss of the skin barrier. A comprehensive review of the impact of burns on micronutrients and the relevance of those micronutrients to recovery from burn injury is beyond the scope of this topic, but vitamins A, C, and D and three trace minerals copper, zinc, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    will be discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Vitamins A, C, and D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin A plays an important role in immune function, wound epithelialization, and prevention of free radical damage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/43\">",
"     43",
"    </a>",
"    ]. Vitamin A toxicity can occur with high doses; vitamin C does not appear to have any known toxicities in high doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin C, an antioxidant, is an essential component of collagen cross-linking and therefore also influences wound healing. Levels of vitamins A and C are decreased in patients following burn injury, but can be replenished with supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D deficiency is most likely due to a combination of acquired defects in vitamin D metabolism and immobility associated with significant burn injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. While vitamin D supplementation has been recommended in burn patients, an optimal dosing or method for delivery has not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/45,47\">",
"     45,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link\">",
"     \"Overview of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Trace minerals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copper, zinc and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    serve as antioxidants. Zinc also plays a role in collagen cross-linking, wound healing, and immune function. The depletion of copper and zinc in burn patients is attributed to a combination of urinary losses and exudative losses from wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The mechanism for the selenium deficiency is unclear and appears to be multifactorial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ESPEN (European Society for Clinical Nutrition and Metabolism) recommends that the trace elements copper, zinc and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    be supplemented in \"higher than standard dose\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/1\">",
"     1",
"    </a>",
"    ]. Doses of 40.4 mmol copper, 2.9 mmol selenium and 406 mmol zinc are recommended for at least 30 days postburn [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/52\">",
"     52",
"    </a>",
"    ]. These ESPEN guidelines were developed by an interdisciplinary expert group in accordance with officially accepted standards and are based on published studies since 1985.",
"   </p>",
"   <p>",
"    A randomized trial evaluated the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21715?source=see_link\">",
"     intravenous copper",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , and zinc (trace element group) in comparison to a placebo vehicle (control group) in 21 severe burn adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/52\">",
"     52",
"    </a>",
"    ]. There was a significant decrease in the median number of pulmonary infections in the trace element group compared with the control group (two versus four per patient) and wound healing was also significantly improved, with fewer requiring regrafting. Other studies have shown that supplementation with trace elements is associated with a shortened hospital stay and improved wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the limited data supporting supernormal repletion of any micronutrients, routine practice at our center is to supplement all adult burn patients simply with an adult multivitamin, and all pediatric burn patients with a pediatric multivitamin. This practice is uniform in U.S. burn centers, although some centers provide Vitamin C and Zinc in addition to a multivitamin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn injury involves loss of water, electrolytes, and protein. Resuscitation with a hypertonic lactated saline solution (eg, lactated Ringer's solution) reduces the risk of electrolyte imbalances and tissue edema [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/55\">",
"     55",
"    </a>",
"    ]. Electrolyte balance, however, must be monitored and corrected throughout all phases of burn care [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/56\">",
"     56",
"    </a>",
"    ]. Hyponatremia and hyperkalemia occur during the initial resuscitation period. Hypernatremia, hypokalemia, hypomagnesemia and hypophosphatemia commonly occur during the early post-resuscitation period and the hypermetabolic phase. &nbsp;We use an electrolyte protocol at our institution to reduce the risk of electrolyte imbalances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FORMULA SELECTION FOR ENTERAL NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred method of nutritional support is by the enteral route. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of nutritional support for moderate to severe burn patients\", section on 'Delivery of nutritional support'",
"    </a>",
"    .) Many commercial preparations exist for this purpose. These formulas come in a variety of compositions, and the \"standard\" adult nutritional formulas can provide appropriate support for wound healing and maintenance of lean body mass when they are used to provide adequate calorie and protein intake. Involvement of a dietician in the initial nutrition support of the burn patient, as well as when changes in physiologic and clinical status occur, is desirable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Immunonutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of immune-modulating supplements or formulas holds particular appeal for patients with the profound hypermetabolic response and immune suppression that are associated with severe burns. However, there is insufficient evidence to support the use of commercially available immune-enhancing formulas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ESPEN (European Society for Clinical Nutrition and Metabolism) has made no recommendation regarding supplementation with alpha-3 fatty acids, arginine, or nucleotides for burned patients due to insufficient data, but recommends that glutamine be added to standard formulas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have generally shown that glutamine is beneficial in the nutritional support of burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/1,2,57-63\">",
"     1,2,57-63",
"    </a>",
"    ]. Enteral glutamine supplementation decreases infectious complications, shortens length of hospital stay, and reduces mortality rates following burn injury. For example, a clinical trial randomly assigned 40 patients sustaining 50 to 80 percent TBSA burns to a glutamine enriched enteral nutrition (0.35 grams",
"    <span class=\"nowrap\">",
"     gln/kg",
"    </span>",
"    body",
"    <span class=\"nowrap\">",
"     weight/day)",
"    </span>",
"    or the standard enteral formulation, within 24 hours of burn injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/61\">",
"     61",
"    </a>",
"    ]. In the group receiving glutamine enriched enteral nutrition, plasma glutamine levels were normalized compared to the persistently low levels in the standard formulation diet group. Compared to the standard formula group, the glutamine enriched group had a significantly shorter length of hospital stay (67 versus 73 days) and greater percent wound healing at day 30 postburn (86 versus 72 percent). Endotoxin levels, which were initially elevated in both groups, decreased significantly in the glutamine enriched group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Branched-chain amino acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The branched-chain amino acids (BCAAs) have anabolic, or at a minimum, anticatabolic properties. Leucine, in particular, has received a lot of attention because plasma leucine levels are typically depleted following a severe burn injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/64\">",
"     64",
"    </a>",
"    ]. However, clinical studies have failed to show any benefit to the administration of supplemental leucine as a component of nutritional support for burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/65\">",
"     65",
"    </a>",
"    ]. At this time, supplementation of BCAAs in burn patients is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Specialty formulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several specialty formulas are commonly used in critical illness in an attempt to reduce renal failure, glucose intolerance, and pulmonary failure. Commercially available formulas for renal failure patients are lower in protein and restrict electrolytes, particularly potassium and phosphate. Many of these formulas use additional carbohydrate calories to compensate for the protein calories that are restricted in renal patients, and some contain additional fat as the source of calories.",
"   </p>",
"   <p>",
"    Formulas that are higher in carbohydrates and lower in fat may be used appropriately in burn patients with renal failure and electrolyte abnormalities, recognizing the likely need to supplement protein in the moderate to severe burn patient population. Formulas available for patients with diabetes or those with stress glucose intolerance are lower in carbohydrates and higher in fat; therefore, this makes them an ineffective choice in burns, since higher-carbohydrate, low-fat diets have been clearly associated with better immune function and lesser loss of lean body mass [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/32,39,41\">",
"     32,39,41",
"    </a>",
"    ]. The use of pulmonary care formulas, designed for use in ARDS to minimize excessive carbon dioxide production via increased fat and decreased carbohydrates, is not recommended for the same reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     NUTRITIONAL SUPPORT ADJUSTMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The energy and nutrient needs of burn patients are heterogeneous through the course of recovery. Nutritional needs fluctuate based upon wound closure and physical activity, and may be impacted by complications such as pneumonia, renal insufficiency, or wound sepsis. The prolonged nature of the hypermetabolic response, which may persist for more than a year following injury, must be considered even after wound healing is complete. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjustments in nutritional support are best conducted under the guidance of an experienced dietician as a member of the care team and using a constellation of techniques that aid in monitoring the adequacy of nutritional support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15716?source=see_link\">",
"     \"Evaluating nutritional support for moderate to severe burn patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ESPEN RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ESPEN recommendations for enteral nutrition in critically ill patients are [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11401/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteral nutrition should be administered to all critically ill patients who are not expected to be taking a full oral diet within three days.",
"     </li>",
"     <li>",
"      Enteral nutrition should be initiated during the first 24 hours using a standard high-protein formula.",
"     </li>",
"     <li>",
"      During the acute and initial phases of critical illness, an exogenous energy supply in excess of 20 to 25",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      body",
"      <span class=\"nowrap\">",
"       weight/day",
"      </span>",
"      should be avoided, whereas, during recovery, the aim should be to provide values of 25 to 30 total",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      body",
"      <span class=\"nowrap\">",
"       weight/day.",
"      </span>",
"     </li>",
"     <li>",
"      Supplementary parenteral nutrition remains a reserve tool and should be given only to those patients who do not reach their target nutrient intake on enteral nutrition alone.",
"     </li>",
"     <li>",
"      Trace minerals copper, zinc and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      should be included in standard doses.",
"     </li>",
"     <li>",
"      Glutamine should be added to standard formulas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The assessment of the energy requirements in burn patients is a composite of the basal metabolic rate, hypermetabolism, percent of total body surface area (TBSA) burned, ventilatory support, infections, sepsis, multiple organ failure, thermic effect of food, and level of physical activity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Determining caloric requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred method to estimate caloric requirements in burn patients is by indirect calorimetry (IDC). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Determining caloric requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IDC requires specialized equipment that may not be readily available. Alternatives for estimating caloric requirements for adult burn patients include the modified Harris-Benedict equation and the Curreri formula (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Determining caloric requirements'",
"      </a>",
"      above). Caution must be used with both formulas to avoid overfeeding.",
"     </li>",
"     <li>",
"      In our practice, we use the",
"      <span class=\"nowrap\">",
"       RDA/RDI",
"      </span>",
"      for pediatric burn patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Determining caloric requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a formula that provides at least 50 percent of calories as carbohydrates, 35 percent as protein, and no more than 15 percent as fat, supplemented with micronutrients and macronutrients. (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Nutrient composition for enteral formulas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our practice, we supplement the enteral formula with a standard multivitamin with trace minerals. These include vitamins A, C, and D, and trace minerals copper, zinc, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      . We also use a standard protocol for electrolyte replacement. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Micronutrients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that glutamine be added to standard enteral formulas (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Formula selection for enteral nutrition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/1\">",
"      Kreymann KG, Berger MM, Deutz NE, et al. ESPEN Guidelines on Enteral Nutrition: Intensive care. Clin Nutr 2006; 25:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/2\">",
"      Martindale RG, McClave SA, Vanek VW, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive Summary. Crit Care Med 2009; 37:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/3\">",
"      Prelack K, Dylewski M, Sheridan RL. Practical guidelines for nutritional management of burn injury and recovery. Burns 2007; 33:14.",
"     </a>",
"    </li>",
"    <li>",
"     American Burn Association. Initial nutritional support of burn patients. In: 2001 Practice guidelines for burn care. Supplement to the Journal of Burn Care and Rehabilitation, Official publication of the American Burn Association.",
"    </li>",
"    <li>",
"     Saffle, JR, Graves, C. Nutritional support of the burned patient. In: Total Burn Care, 3rd Edition, Herndon, DN (Ed), Saunders Elsevier, Philadelphia, PA 2007. p. 398.",
"    </li>",
"    <li>",
"     Spodaryk, M, Kobylarz, K. The usability of Harris-Benedict and Curreri equations in nutritional management of thermal injuries. Annals of Burns and Fire Disasters 2005; 18:117. Available online at: www.medbc.com/annals/review/vol_18/num_3/text/vol18n3p117.asp (Accessed June, 8 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/7\">",
"      Hart DW, Wolf SE, Herndon DN, et al. Energy expenditure and caloric balance after burn: increased feeding leads to fat rather than lean mass accretion. Ann Surg 2002; 235:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/8\">",
"      Gottschlich, MM, Ireton-Jones, CS. Classic article: The Curreri formula: A landmark process for estimating the caloric needs of burn patients. Nutr Clin Pract 2001; 16:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/9\">",
"      Curreri PW, Richmond D, Marvin J, Baxter CR. Dietary requirements of patients with major burns. J Am Diet Assoc 1974; 65:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/10\">",
"      Allard JP, Pichard C, Hoshino E, et al. Validation of a new formula for calculating the energy requirements of burn patients. JPEN J Parenter Enteral Nutr 1990; 14:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/11\">",
"      Hildreth MA, Herndon DN, Desai MH, Broemeling LD. Current treatment reduces calories required to maintain weight in pediatric patients with burns. J Burn Care Rehabil 1990; 11:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/12\">",
"      Dickerson RN, Gervasio JM, Riley ML, et al. Accuracy of predictive methods to estimate resting energy expenditure of thermally-injured patients. JPEN J Parenter Enteral Nutr 2002; 26:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/13\">",
"      Liusuwan RA, Palmieri TL, Kinoshita L, Greenhalgh DG. Comparison of measured resting energy expenditure versus predictive equations in pediatric burn patients. J Burn Care Rehabil 2005; 26:464.",
"     </a>",
"    </li>",
"    <li>",
"     Endorf, FW, Gibran, NS. Burns. In: Schwartz's Principles of Surgery, 9th Edition, Brunicardi, FC, Andersen, DK, Billiar, TR, et al (Eds), McGraw-Hill 2009. p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/15\">",
"      Boullata J, Williams J, Cottrell F, et al. Accurate determination of energy needs in hospitalized patients. J Am Diet Assoc 2007; 107:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/16\">",
"      McClave SA, Snider HL. Use of indirect calorimetry in clinical nutrition. Nutr Clin Pract 1992; 7:207.",
"     </a>",
"    </li>",
"    <li>",
"     Norbury, WB, Herndon, DN. Modulation of the hypermetabolic response after burn injury. In: Total Burn Care, 3rd Edition, Herndon, DN (Ed), Saunders Elsevier, Philadelphia, PA 2007. p. 420.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/18\">",
"      Herndon DN, Curreri PW. Metabolic response to thermal injury and its nutritional support. Cutis 1978; 22:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/19\">",
"      Lam NN, Tien NG, Khoa CM. Early enteral feeding for burned patients--an effective method which should be encouraged in developing countries. Burns 2008; 34:192.",
"     </a>",
"    </li>",
"    <li>",
"     Tancheva, D, Arabadziev, J, Gergov, G, et al. Comparison of estimated energy requirements in severely burned patients with measurements by using indirect calorimetry. Annals of Burns and Fire Disasters 2005; 18:16. Available online at: www.medbc.com/annals/review/vol_18/num_1/text/vol18n1p16.asp (Accessed June 8, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/21\">",
"      Stucky CC, Moncure M, Hise M, et al. How accurate are resting energy expenditure prediction equations in obese trauma and burn patients? JPEN J Parenter Enteral Nutr 2008; 32:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/22\">",
"      Cunningham JJ. Body composition as a determinant of energy expenditure: a synthetic review and a proposed general prediction equation. Am J Clin Nutr 1991; 54:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/23\">",
"      Royall D, Fairholm L, Peters WJ, et al. Continuous measurement of energy expenditure in ventilated burn patients: an analysis. Crit Care Med 1994; 22:399.",
"     </a>",
"    </li>",
"    <li>",
"     Dietary Reference Intakes (DRIs): Recommended intakes for individuals, vitamins. Food and Nutrition Board, Institute of Medicine of the US National Academies 2004. Available online at: www.iom.edu/reports (Accessed on June 9, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/25\">",
"      Graves C, Saffle J, Cochran A. Actual burn nutrition care practices: an update. J Burn Care Res 2009; 30:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/26\">",
"      Hildreth MA, Herndon DN, Desai MH, Broemeling LD. Caloric requirements of patients with burns under one year of age. J Burn Care Rehabil 1993; 14:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/27\">",
"      Hildreth MA, Herndon DN, Desai MH, Duke MA. Reassessing caloric requirements in pediatric burn patients. J Burn Care Rehabil 1988; 9:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/28\">",
"      Jeejeebhoy KN. Permissive underfeeding of the critically ill patient. Nutr Clin Pract 2004; 19:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/29\">",
"      Dickerson RN, Boschert KJ, Kudsk KA, Brown RO. Hypocaloric enteral tube feeding in critically ill obese patients. Nutrition 2002; 18:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/30\">",
"      Choban PS, Burge JC, Scales D, Flancbaum L. Hypoenergetic nutrition support in hospitalized obese patients: a simplified method for clinical application. Am J Clin Nutr 1997; 66:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/31\">",
"      Dickerson RN, Rosato EF, Mullen JL. Net protein anabolism with hypocaloric parenteral nutrition in obese stressed patients. Am J Clin Nutr 1986; 44:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/32\">",
"      Hart DW, Wolf SE, Zhang XJ, et al. Efficacy of a high-carbohydrate diet in catabolic illness. Crit Care Med 2001; 29:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/33\">",
"      Yu YM, Tompkins RG, Ryan CM, Young VR. The metabolic basis of the increase of the increase in energy expenditure in severely burned patients. JPEN J Parenter Enteral Nutr 1999; 23:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/34\">",
"      Wolfe RR, Goodenough RD, Burke JF, Wolfe MH. Response of protein and urea kinetics in burn patients to different levels of protein intake. Ann Surg 1983; 197:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/35\">",
"      Agus MS, Jaksic T. Nutritional support of the critically ill child. Curr Opin Pediatr 2002; 14:470.",
"     </a>",
"    </li>",
"    <li>",
"     Demling, RH. Nutrition, Anabolism, and the Wound Healing Process: An Overview. Eplasty 2009. Available online at: www.eplasty.com./index.php?option=com_content&amp;view=article&amp;id=272&amp;catid=170:volume-09-eplasty-2009 (Accessed on April 23, 2010).",
"    </li>",
"    <li>",
"     Baytieh, L, Carr-Thompson, A, Fox, V, et al. Nutrition and dietetics principles and guidelines for adult and pediatric burns patient management. New South Wales Severe Burn Injury Service, Sydney, Australia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/38\">",
"      Burke JF, Wolfe RR, Mullany CJ, et al. Glucose requirements following burn injury. Parameters of optimal glucose infusion and possible hepatic and respiratory abnormalities following excessive glucose intake. Ann Surg 1979; 190:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/39\">",
"      Garrel DR, Razi M, Larivi&egrave;re F, et al. Improved clinical status and length of care with low-fat nutrition support in burn patients. JPEN J Parenter Enteral Nutr 1995; 19:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/40\">",
"      Gottschlich MM, Jenkins M, Warden GD, et al. Differential effects of three enteral dietary regimens on selected outcome variables in burn patients. JPEN J Parenter Enteral Nutr 1990; 14:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/41\">",
"      Mochizuki H, Trocki O, Dominioni L, et al. Optimal lipid content for enteral diets following thermal injury. JPEN J Parenter Enteral Nutr 1984; 8:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/42\">",
"      Masters B, Aarabi S, Sidhwa F, Wood F. High-carbohydrate, high-protein, low-fat versus low-carbohydrate, high-protein, high-fat enteral feeds for burns. Cochrane Database Syst Rev 2012; 1:CD006122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/43\">",
"      Mayes T, Gottschlich MM, Warden GD. Clinical nutrition protocols for continuous quality improvements in the outcomes of patients with burns. J Burn Care Rehabil 1997; 18:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/44\">",
"      Rock CL, Dechert RE, Khilnani R, et al. Carotenoids and antioxidant vitamins in patients after burn injury. J Burn Care Rehabil 1997; 18:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/45\">",
"      Gottschlich MM, Mayes T, Khoury J, Warden GD. Hypovitaminosis D in acutely injured pediatric burn patients. J Am Diet Assoc 2004; 104:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/46\">",
"      Klein GL, Langman CB, Herndon DN. Vitamin D depletion following burn injury in children: a possible factor in post-burn osteopenia. J Trauma 2002; 52:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/47\">",
"      Klein GL, Herndon DN, Chen TC, et al. Standard multivitamin supplementation does not improve vitamin D insufficiency after burns. J Bone Miner Metab 2009; 27:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/48\">",
"      Berger MM, Cavadini C, Bart A, et al. Cutaneous copper and zinc losses in burns. Burns 1992; 18:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/49\">",
"      Voruganti VS, Klein GL, Lu HX, et al. Impaired zinc and copper status in children with burn injuries: need to reassess nutritional requirements. Burns 2005; 31:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/50\">",
"      Berger MM, Cavadini C, Bart A, et al. Selenium losses in 10 burned patients. Clin Nutr 1992; 11:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/51\">",
"      Gamliel Z, DeBiasse MA, Demling RH. Essential microminerals and their response to burn injury. J Burn Care Rehabil 1996; 17:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/52\">",
"      Berger MM, Baines M, Raffoul W, et al. Trace element supplementation after major burns modulates antioxidant status and clinical course by way of increased tissue trace element concentrations. Am J Clin Nutr 2007; 85:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/53\">",
"      Berger MM, Spertini F, Shenkin A, et al. Trace element supplementation modulates pulmonary infection rates after major burns: a double-blind, placebo-controlled trial. Am J Clin Nutr 1998; 68:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/54\">",
"      Berger MM, Eggimann P, Heyland DK, et al. Reduction of nosocomial pneumonia after major burns by trace element supplementation: aggregation of two randomised trials. Crit Care 2006; 10:R153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/55\">",
"      Bortolani A, Governa M, Barisoni D. Fluid replacement in burned patients. Acta Chir Plast 1996; 38:132.",
"     </a>",
"    </li>",
"    <li>",
"     Ramos, CG. Management of fluid and electrolyte disturbances in the burn patient. Annals of Burns and Fire Disasters 2000; 13:201. www.medbc.com/annals/review/vol_13/num_4/text/vol13n4p201.htm (Accessed June 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/57\">",
"      Saffle JR, Wiebke G, Jennings K, et al. Randomized trial of immune-enhancing enteral nutrition in burn patients. J Trauma 1997; 42:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/58\">",
"      Garrel D, Patenaude J, Nedelec B, et al. Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Crit Care Med 2003; 31:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/59\">",
"      Wibbenmeyer LA, Mitchell MA, Newel IM, et al. Effect of a fish oil and arginine-fortified diet in thermally injured patients. J Burn Care Res 2006; 27:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/60\">",
"      Wischmeyer PE, Lynch J, Liedel J, et al. Glutamine administration reduces Gram-negative bacteremia in severely burned patients: a prospective, randomized, double-blind trial versus isonitrogenous control. Crit Care Med 2001; 29:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/61\">",
"      Zhou YP, Jiang ZM, Sun YH, et al. The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial. JPEN J Parenter Enteral Nutr 2003; 27:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/62\">",
"      Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 2008; 34:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/63\">",
"      Windle EM. Glutamine supplementation in critical illness: evidence, recommendations, and implications for clinical practice in burn care. J Burn Care Res 2006; 27:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/64\">",
"      De Bandt JP, Cynober L. Therapeutic use of branched-chain amino acids in burn, trauma, and sepsis. J Nutr 2006; 136:308S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11401/abstract/65\">",
"      Yu YM, Wagner DA, Walesreswski JC, et al. A kinetic study of leucine metabolism in severely burned patients. Comparison between a conventional and branched-chain amino acid-enriched nutritional therapy. Ann Surg 1988; 207:421.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 820 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11401=[""].join("\n");
var outline_f11_8_11401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINING CALORIC REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial nutritional support goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Calculating energy requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Indirect calorimetry estimation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Harris-Benedict equation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Curreri formula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cunningham prediction equation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Toronto formula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pediatric formulas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - RDA/RDI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Curreri Junior",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Galveston Shriners Burns Institute",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Permissive underfeeding for obese patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NUTRIENT COMPOSITION FOR ENTERAL FORMULAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Macronutrients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Micronutrients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Vitamins A, C, and D",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Trace minerals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Electrolytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FORMULA SELECTION FOR ENTERAL NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Immunonutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Branched-chain amino acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Specialty formulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      NUTRITIONAL SUPPORT ADJUSTMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ESPEN RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/820\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/820|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/7/28795\" title=\"table 1\">",
"      Burn nutr RDI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/62/4075\" title=\"table 2\">",
"      Burn nutr curreri j",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/22/10603\" title=\"table 3\">",
"      Burn nutr shriners",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15716?source=related_link\">",
"      Evaluating nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=related_link\">",
"      Overview of nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_8_11402="Diagnosis and treatment of endometriosis in adolescents";
var content_f11_8_11402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of endometriosis in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/8/11402/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11402/contributors\">",
"     Marc R Laufer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/8/11402/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11402/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11402/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/8/11402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/8/11402/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/8/11402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriosis refers to the presence of endometrial glands and stroma outside the endometrial cavity and uterine musculature. These ectopic endometrial implants are usually located in the pelvis, but can occur nearly anywhere in the body. The disease can be associated with many distressing and debilitating symptoms, or it may be asymptomatic. Despite numerous studies, considerable controversy remains regarding the incidence, pathogenesis, natural history, and optimal treatment of this disorder.",
"   </p>",
"   <p>",
"    This topic will discuss endometriosis specifically in adolescents. The disease in adults is reviewed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link\">",
"       \"Overview of the treatment of endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link\">",
"       \"Diagnosis and management of ovarian endometriomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8761?source=see_link\">",
"       \"Gonadotropin releasing hormone agonists for long-term treatment of endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link\">",
"       \"Pathogenesis and treatment of infertility in women with endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link\">",
"       \"Reproductive surgery for female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=see_link\">",
"       \"Thoracic endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of endometriosis in the general population is not known; estimates vary depending upon the population studied (symptomatic or asymptomatic) and the method of diagnosis (clinical versus surgical). The disease has been reported in 25 to 38 percent of adolescents with chronic pelvic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] and 47 percent of those with chronic pelvic pain that undergo laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence among adolescents undergoing laparoscopy for pelvic pain not controlled with oral contraceptive pills (OCs) and nonsteroidal anti-inflammatory drugs (NSAIDs) is 50 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-thirds of adult women with endometriosis report that their symptoms started before age 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/7\">",
"     7",
"    </a>",
"    ]. Although it had been assumed that endometriosis presented only after many years of menstruation, this was incorrect: symptomatic cases have been documented prior to menarche in girls who have some breast development, and others soon after menarche [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some adolescents may have a genetic predisposition to developing endometriosis. In one study of 123 patients with histologically proved endometriosis, first degree female relatives of affected patients were significantly more likely to have been diagnosed with endometriosis than relatives of controls (7 versus 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many theories have been proposed to explain the etiology of endometriosis. No single theory explains all cases, and all of the theories help to explain some aspects of the disease. The types and frequencies of pathogenetic mechanisms may be different in adolescents and",
"    <span class=\"nowrap\">",
"     postpubertal/premenarchal",
"    </span>",
"    endometriosis than in adult endometriosis. It is likely that the cause of endometriosis is multifactorial, with contributions from several of the proposed mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following theories for the pathogenesis of endometriosis have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The implantation or retrograde menstruation theory suggests that endometrial tissue from the uterus is shed during menstruation and transported through the fallopian tubes, thereby gaining access to, and implanting on, pelvic structures [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This theory is supported by the observation that endometriosis occurs most commonly in the dependent portion of the pelvis. In addition, obstructive congenital anomalies of the female genital tract that enhance retrograde flow have been associated with endometriosis in the adolescent population [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/9,13,14\">",
"       9,13,14",
"      </a>",
"      ]. As an example, one series identified six adolescents with m&uuml;llerian anomalies and endometriosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/13\">",
"       13",
"      </a>",
"      ]. The youngest patient was a 12-year-old with vaginal atresia and bicornuate uterus who developed hematocolpos, likely followed by retrograde flow leading to her endometriosis. Repair of this type of obstructive anomaly has been associated with resolution of endometriosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/14\">",
"       14",
"      </a>",
"      ], but in our experience, this has not been true in all cases.",
"     </li>",
"     <li>",
"      Endometriosis in locations outside the pelvis is explained by dissemination of endometrial cells or tissue through lymphatics and blood vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The coelomic metaplasia theory proposes that the coelomic (peritoneal) cavity contains undifferentiated cells or cells capable of dedifferentiating into endometrial tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/16\">",
"       16",
"      </a>",
"      ]. This theory is based upon embryologic studies demonstrating that all pelvic organs, including the endometrium, are derived from cells lining the coelomic cavity. Support for this theory derives from the observation of endometriosis in premenarchal girls who have some breast development [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/8,17,18\">",
"       8,17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The direct transplantation theory is the probable explanation for endometriosis that develops in episiotomy, hysterotomy, and other surgical scars.",
"     </li>",
"     <li>",
"      The cellular immunity theory, which is the most recently proposed hypothesis, suggests that a deficiency in cellular immunity allows ectopic endometrial tissue to proliferate [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appreciation of the clinical manifestations of endometriosis in the adolescent may decrease the length of time between patient presentation and clinical diagnosis, which averages nine years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/7\">",
"     7",
"    </a>",
"    ]. Ideally, early diagnosis and treatment of endometriosis will retard disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/22\">",
"     22",
"    </a>",
"    ], and decrease the adverse long-term effects of the disease (chronic pain, endometriomas, infertility), and thus improve the quality of life of adolescents and women with this disorder.",
"   </p>",
"   <p>",
"    Adolescents with endometriosis usually have both acyclic and cyclic pain (severe, progressive dysmenorrhea) (",
"    <a class=\"graphic graphic_table graphicRef72066 \" href=\"UTD.htm?8/38/8811\">",
"     table 1",
"    </a>",
"    ); isolated cyclic pain is the least common pain presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/6\">",
"     6",
"    </a>",
"    ]. Bowel symptoms (eg, rectal pain, constipation, painful defecation that may be cyclic, rectal bleeding) and bladder symptoms (eg, dysuria, urgency, hematuria) are also common [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/6\">",
"     6",
"    </a>",
"    ], while ovarian endometriomas and infertility are rare in adolescents.",
"   </p>",
"   <p>",
"    In contrast, adults with endometriosis commonly have cyclic pain, and present with dysmenorrhea, dyspareunia, a pelvic mass, infertility, or chronic pelvic pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of pelvic pain in adolescents include appendicitis, pelvic inflammatory disease, m&uuml;llerian abnormalities with outflow obstruction, hernia, bowel disease, and psychosocial issues. The etiology and evaluation of chronic pain in this population are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questions that should be addressed by the history are listed in the figure (",
"    <a class=\"graphic graphic_table graphicRef76235 \" href=\"UTD.htm?20/42/21163\">",
"     table 2",
"    </a>",
"    ). Having the patient keep a diary documenting the frequency and character of her pain will help determine whether the pain is cyclic, and if it is related to bowel or bladder function. Patients with a history of sexual or physical abuse may be at increased risk of developing chronic pelvic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/23\">",
"     23",
"    </a>",
"    ], but this should not preclude further evaluation for endometriosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the physical examination is to determine the etiology of the pain and to rule out an ovarian tumor or anomaly of the reproductive tract. The approach to abdominopelvic examination depends on the patient. Although important, it may not be possible to perform a complete pelvic examination in all adolescents. For adolescents who are not sexually active, rectal-abdominal examination may be better tolerated than vaginal-abdominal (ie, bimanual) examination; a bimanual pelvic examination is not a requirement for evaluation of adolescent pelvic pain. A Q-tip can be inserted into the vagina to document patency and exclude obstructive or partially obstructive anomalies such as a transverse vaginal septum, imperforate or microperforate hymen, vaginal agenesis, or an obstructed hemivagina. Anomalies are present in about 5 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The abdominal examination is usually normal. On pelvic examination, adolescents rarely have uterosacral nodularity, a common finding in adults with the disease, but pain in the cul-de-sac is common. Adnexal enlargement may be palpable if an endometrioma is present, but these masses are also rare in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/25\">",
"     25",
"    </a>",
"    ]. Sonographic examination should be performed to augment a limited physical examination and",
"    <span class=\"nowrap\">",
"     identify/exclude",
"    </span>",
"    causes of abdominopelvic pain other than endometriosis. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Imaging studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nongynecologic physical findings that are observed more frequently among women with endometriosis are red hair color, scoliosis, and dysplastic nevi [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count and erythrocyte sedimentation rate, which may suggest the presence of an acute or chronic inflammatory process",
"     </li>",
"     <li>",
"      Urinalysis and urine culture to identify pain originating in the urinary tract (eg, cystitis, stone)",
"     </li>",
"     <li>",
"      Pregnancy test and tests for sexually transmitted infections (gonorrhea, chlamydia), when appropriate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CA 125 is most commonly used as a biomarker for ovarian cancer, but can be elevated in other conditions, including endometriosis. A serum CA 125 level is not a useful screening test due to its high rate of false positives (",
"    <a class=\"graphic graphic_table graphicRef81621 \" href=\"UTD.htm?12/48/13069\">",
"     table 3",
"    </a>",
"    ). It has been used occasionally to follow the progress of disease in patients who have histologically or visually confirmed endometriosis at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/29\">",
"     29",
"    </a>",
"    ], but we prefer to rely on the patient's report of symptoms to follow endometriosis, and do not use CA 125 in clinical management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H18#H18\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Serum CA 125'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adult women with endometriosis, sonography can identify an endometrioma, which is one of the presentations of the disease. Imaging is less useful in diagnosis of endometriosis in adolescents since endometriomas rarely occur and typical lesions of adolescent endometriosis cannot be appreciated with ultrasound. However, ultrasound may be useful to",
"    <span class=\"nowrap\">",
"     identify/exclude",
"    </span>",
"    several structural causes of pelvic pain in adolescents, such as ovarian torsion or hemorrhage, tumors, genital tract anomalies, and appendicitis. (See individual topic reviews).",
"   </p>",
"   <p>",
"    Magnetic resonance imaging can be helpful to better define an abnormality suspected by sonography, but should not be used as a first-line imaging test because of its expense and poor sensitivity for detecting peritoneal lesions or staging endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Computed tomography is also an insensitive test in the diagnostic evaluation of endometriosis, unless an endometrioma is identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link\">",
"     \"Diagnosis and management of ovarian endometriomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TRIAL OF MEDICAL THERAPY FOR DYSMENORRHEA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     NSAIDs and hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical treatment of dysmenorrhea is appropriate prior to considering surgical intervention for",
"    <span class=\"nowrap\">",
"     diagnosis/treatment",
"    </span>",
"    of endometriosis in adolescents with dysmenorrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who have difficulty participating in normal activities, are missing school, or avoiding extracurricular activities because of pelvic pain. A three-month trial of nonsteroidal anti-inflammatory agents (NSAIDs) is a reasonable approach when the pain evaluation suggests a nonacute gynecological source, such as primary dysmenorrhea or endometriosis (",
"    <a class=\"graphic graphic_table graphicRef71912 \" href=\"UTD.htm?28/52/29516\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/24\">",
"     24",
"    </a>",
"    ]. The medication should be started before the expected onset of severe pain, if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31125?source=see_link\">",
"     \"Primary dysmenorrhea in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hormonal therapy, such as a cyclic low-dose combination",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    oral contraceptive pill (OC), or progestin only therapy (oral, injectable, or implantable), should be given with the NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/24\">",
"     24",
"    </a>",
"    ]. Use of hormonal therapy leads to decidualization and subsequent atrophy of ectopic and eutopic endometrial tissue, thereby decreasing bleeding and, in turn, reducing bleeding-related pain. These agents are particularly useful in adolescents also needing contraception. The vaginal ring and transdermal contraceptive patch are other examples of methods of combined hormonal contraception and are acceptable alternatives to OCs. All of these methods are safe and effective if given cyclically or in an extended or continuous cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The extended cycle regimen has been successful in women whose pain did not respond to cyclic therapy, but is associated with more unscheduled bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the treatment of endometriosis\", section on 'Estrogen-progestin oral contraceptives'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the treatment of endometriosis\", section on 'Initial approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link\">",
"     \"Hormonal contraception for suppression of menstruation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link&amp;anchor=H17974499#H17974499\">",
"     \"Contraception: Overview of issues specific to adolescents\", section on 'Extended-cycle or continuous pill use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the pain does not resolve with NSAIDs and hormonal therapy, then further evaluation is necessary to determine whether endometriosis is the etiology of the pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gonadotropin releasing hormone agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;For adult women in whom endometriosis is the suspected cause of the pain, an expert panel opined that a trial of medical therapy with a GnRH agonist is justified provided that there are no other indications for surgery (eg, suspicious adnexal mass) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/36\">",
"     36",
"    </a>",
"    ]. The empiric utilization of a gonadotropin releasing hormone (GnRH) agonist allows patients with chronic pelvic pain and a high probability of endometriosis to avoid a diagnostic surgical procedure before beginning this therapy. Doses are described below (see",
"    <a class=\"local\" href=\"#H21\">",
"     'GnRH agonists'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Placebo controlled randomized trials have confirmed the efficacy of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/37\">",
"     37",
"    </a>",
"    ]. The only randomized trial that directly compared use of a GnRH agonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    ) to low-dose cyclic OCs in adult women with pelvic pain associated with endometriosis showed that both drugs provided significant relief of pain, but goserelin was superior for treatment of dyspareunia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not utilize empiric GnRH agonists for adolescents 18 years of age or younger because we have concerns about potential adverse long-term effects on bone formation and bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/39\">",
"     39",
"    </a>",
"    ]. Additionally, some parents are not comfortable with a trial of empiric therapy due to worries about using a medication with adverse side effects without a definitive diagnosis. The American College of Obstetricians and Gynecologists does not endorse the use of empiric GnRH agonist therapy for treatment of presumed endometriosis in young women under age 18, but considers it an option for consenting women age 18 or over [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/24\">",
"     24",
"    </a>",
"    ]. Most bone mass in females has accumulated by age 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PATIENTS WHO FAIL THERAPY FOR DYSMENORRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis should be established before administering further treatment to adolescents who have persistent pain after three to six months of hormonal therapy and NSAIDS for the treatment of dysmenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/24\">",
"     24",
"    </a>",
"    ]. Laparoscopy is the gold standard for diagnosis of endometriosis.",
"   </p>",
"   <p>",
"    When pain persists despite dysmenorrhea therapy, we talk with the adolescent and her family to determine the amount of pain that she is experiencing. We suggest that if her pain interferes with her daily life's activities or places her at a disadvantage in academics, sports, or social activities compared with others, then she should undergo laparoscopy for definitive diagnosis. Typically, laparoscopy is performed after three to six months of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/24\">",
"     24",
"    </a>",
"    ], but waiting this long may interfere with school and social activities. Therefore, it may be necessary to proceed with laparoscopic evaluation sooner. At surgery, up to 70 percent of adolescents with chronic pelvic pain that has not responded to a trial of NSAIDs and cyclic OCs are found to have endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/6\">",
"     6",
"    </a>",
"    ]. These data are from studies in the early 1990s. Based on advances in laparoscopic imaging with high definition digital technology, the current rate is likely higher.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnostic (and therapeutic) laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a gynecologist performs the laparoscopy, he or she must have experience operating on patients in this age range, otherwise a pediatric gynecologist or pediatric surgeon should be consulted. A diagnostic laparoscopy with subsequent referral to a specialist for definitive surgery places the patient at undue risk from two anesthesias. Therefore, the surgical procedure should be both diagnostic and therapeutic, with surgical management of the endometriosis.",
"   </p>",
"   <p>",
"    It is especially important to achieve a good cosmetic result in adolescents. To minimize visible scarring, the laparoscope trocar can be placed through a vertical incision directly in the umbilicus. Additional operative ports should be placed symmetrically 1 to 2 cm above the pubic symphysis so that the pubic hair will grow over the incision site(s).",
"   </p>",
"   <p>",
"    The gynecologist operating on an adolescent with pelvic pain must be familiar with the appearance of endometriosis implants in this age group. The implants have variable morphology (",
"    <a class=\"graphic graphic_picture graphicRef65789 \" href=\"UTD.htm?24/18/24868\">",
"     picture 1",
"    </a>",
"    ), which has been described in the revised American Society of Reproductive Medicine (ASRM) Classification of Endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only series that objectively compared endometriosis lesions in adolescents to those in adults found red flame lesions were more common and powder burn lesions less common in adolescents than in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/42\">",
"     42",
"    </a>",
"    ]. This is consistent with the presumption that powder burn lesions represent older, more advanced implants. Clear and red lesions may be the more painful lesions of endometriosis (",
"    <a class=\"graphic graphic_table graphicRef65934 \" href=\"UTD.htm?1/46/1771\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/43\">",
"     43",
"    </a>",
"    ]. Peritoneal windows or defects are also common in adolescents and should be recognized as diagnostic of endometriosis.",
"   </p>",
"   <p>",
"    Care must be taken to identify subtle endometriotic lesions that often appear as clear, shiny peritoneal vesicles. Visualization through a liquid medium, such as saline, may facilitate identification [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/44\">",
"     44",
"    </a>",
"    ]. After all the lesions have been located, the fluid is removed so that the lesions can be ablated or excised.",
"   </p>",
"   <p>",
"    If no evidence of endometriosis is identified, a posterior cul-de-sac biopsy to exclude the presence of microscopic disease should be performed and may identify lesions not visualized on laparoscopy. One study of nondirected biopsies found a low prevalence of microscopic endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/45\">",
"     45",
"    </a>",
"    ], while another reported a significant rate in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/46\">",
"     46",
"    </a>",
"    ]. Our experience at Children's Hospital, Boston, is that we find microscopic endometriosis in 3 percent of adolescent girls with chronic pelvic pain unresponsive to conventional therapy and with a visually normal pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endometriosis should be staged according to the revised ASRM Classification of Endometriosis (",
"    <a class=\"graphic graphic_figure graphicRef66366 \" href=\"UTD.htm?17/34/17954\">",
"     figure 1",
"    </a>",
"    ) to facilitate follow-up and comparison if future surgery is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/41\">",
"     41",
"    </a>",
"    ]. Although most adolescents present with Stage I to II disease, in one series, 11 of 36 adolescents with endometriosis had stage IV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/42\">",
"     42",
"    </a>",
"    ]. In general, the stage of disease does not correlate with degree of pain. When counseling patients postoperatively, it is important to remember that the severity of symptoms does not correlate with the extent or location of lesions (",
"    <a class=\"graphic graphic_table graphicRef75516 \" href=\"UTD.htm?2/25/2459\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most adult women experience a reduction in pain after surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. There are no large studies in adolescents.",
"   </p>",
"   <p>",
"    Electrocautery, endocoagulation, or laser ablation or resection of implants should be performed at the time of diagnostic laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/50\">",
"     50",
"    </a>",
"    ]. In adults with Stage I or II disease, there is no difference in outcome with excision versus ablation of endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/51\">",
"     51",
"    </a>",
"    ]. Lysis of adhesions is also performed at the time of surgery. Laparotomy is rarely required. Any large endometriotic cysts should be removed, with preservation of as much ovarian tissue as possible. Care must be taken to avoid damage to the ureters, major blood vessels, bowel, and bladder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the treatment of endometriosis\", section on 'Conservative surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, surgery alone is not adequate treatment for endometriosis as there can be microscopic residual disease that must be suppressed with medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/36\">",
"     36",
"    </a>",
"    ]. Symptoms will return within one year in approximately 50 percent of adult women who receive only surgical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/36,48,52,53\">",
"     36,48,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MEDICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no long-term follow-up data describing the natural history of untreated endometriosis first detected in adolescents; we do not know the proportion of endometriosis that will progress to more advanced disease if left untreated.",
"   </p>",
"   <p>",
"    The general consensus is that adolescents with histologically confirmed endometriosis should receive medical treatment after surgical",
"    <span class=\"nowrap\">",
"     ablation/resection",
"    </span>",
"    until they have completed childbearing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/24\">",
"     24",
"    </a>",
"    ]. Compared to eutopic endometrium, endometriotic implants are characterized by overproduction of prostaglandins and local production of estrogens and cytokines, which synergize the activities of each other, promote implantation of ectopic endometrium, and cause the pain associated with endometriosis. The rationale for medical therapy is inhibition of prostaglandin synthesis, decidualization and subsequent atrophy of residual ectopic endometrial tissue, and reduction of ovarian estrogen production, thereby inhibiting the growth and activity of the ectopic endometrium.",
"   </p>",
"   <p>",
"    The goal of medical therapy is to manage pain due to residual disease, allow the patient to function comfortably in her daily activities, and suppress disease progression, which could impair fertility. Long-term follow-up data in adolescents show that endometriosis that is surgically identified and destroyed and then followed by medical therapy tends not to progress [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/22,54\">",
"     22,54",
"    </a>",
"    ]. There are limited data on the course of adolescents who undergo complete excision of visible endometriosis but do not undertake postoperative hormonal suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment efficacy should be assessed regularly by asking the patient to rate her pain on a scale of 0 to 10 at each visit. She should be aware that she may not become pain free, but her medications can be adjusted to maximize pain relief and promote participation in school and social activities. Support groups for adolescents with endometriosis are available and can be useful (",
"    <a class=\"external\" href=\"file://www.youngwomenshealth.org/\">",
"     www.youngwomenshealth.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several medical therapies are available, each with differing risks, benefits, and side effect profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/56\">",
"     56",
"    </a>",
"    ]. The choice of treatment depends upon the severity of the patient's symptoms, the extent of disease, and compliance. Although numerous options have been described for the treatment of endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/4,39\">",
"     4,39",
"    </a>",
"    ], combination hormonal therapy or GnRH agonists are usually used for first-line therapy. For adolescents with confirmed endometriosis, we offer both therapies to those ages 16 or over, but use only continuous combination hormonal therapy in those under 16 years of age out of concern about the effects of GnRH agonists on the formation of normal bones and bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Continuous hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of continuous hormonal therapy after surgery may retard progression of disease and control any remaining pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'NSAIDs and hormonal therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6499963\">",
"    <span class=\"h3\">",
"     Combination estrogen/progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy can be used to suppress menstruation and induce a &ldquo;pseudo-pregnancy&rdquo; state for suppression of endometriosis and endometriosis associated pain. A monophasic progestin dominant pill is most effective for the suppression of menses. It is important for adolescents to be reminded that, for this treatment to be successful, the pill must be taken at the same time daily. We typically recommend 6:00 pm, 7:00 pm, or 8:00 pm. We recommend that the pill not be taken upon wakening, as most adolescents do not get up at the same time on weekdays and weekends. If the pill is taken late, there appears to be an increased risk of breakthrough bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestins inhibit endometriotic tissue growth by causing initial decidualization and eventual atrophy. They also inhibit pituitary gonadotropin secretion and ovarian hormone production, resulting in a mildly hypoestrogenic state relative to normal.",
"   </p>",
"   <p>",
"    The most commonly used progestational agents are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       Norethindrone acetate",
"      </a>",
"      (5 to 15 mg daily by mouth)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       Medroxyprogesterone acetate",
"      </a>",
"      (30 to 50 mg daily by mouth)",
"     </li>",
"     <li>",
"      Depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (150 mg intramuscularly every one to three months)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these therapies improves symptoms in approximately 80 to 100 percent of patients with endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    subdermal implant has also been used successfully; but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the treatment of endometriosis\", section on 'Progestins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential bothersome side effects of progestins include weight gain, bloating, depression, and unscheduled bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/7\">",
"     7",
"    </a>",
"    ]; however, many patients tolerate this therapy very well [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/61\">",
"     61",
"    </a>",
"    ]. Oral progestin therapy should be considered prior to long-term intramuscular injections so that side effects can be identified and addressed or the medication easily discontinued.",
"   </p>",
"   <p>",
"    The long-term utilization of depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    has been shown to result in loss of bone density, which is reversible after discontinuation of the progestin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"     \"Depot medroxyprogesterone acetate for contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     GnRH agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;GnRH agonists can be prescribed for adolescents, with laparoscopically confirmed endometriosis, who are at least 16 years old. Our preference is depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate (11.25 mg intramuscularly every three months); it is",
"    <strong>",
"     always",
"    </strong>",
"    given with add-back therapy. We use the three-month formulation to improve compliance with therapy. Some patients who receive a one-month formulation experience the expected &ldquo;flare effect&rdquo; (increased pain and bleeding) and then do not return for their second one-month injection. With the three-month formulation, patients who have increased pain and bleeding with the flare effect will have the GnRH agonist in their system for three months and thus continue to benefit from the subsequent suppression.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26580?source=see_link\">",
"     Nafarelin",
"    </a>",
"    nasal spray (one puff twice daily intranasally) is an alternative GnRH agonist; however, compliance is often unpredictable in the adolescent population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8761?source=see_link\">",
"     \"Gonadotropin releasing hormone agonists for long-term treatment of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over 90 percent of patients will become amenorrheic and hypoestrogenic on this dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/66\">",
"     66",
"    </a>",
"    ]. Side effects include hot flashes, headaches, difficulty sleeping, mood swings, depression, and vaginal dryness; therefore, we do not utilize GnRH agonist therapy without add-back therapy. Menses typically return 60 to 90 days after cessation of intramuscular leuprolide therapy.",
"   </p>",
"   <p>",
"    Generally, initial treatment with a GnRH agonist is continued for six months. Upon completion of this initial six-month course of GnRH agonist therapy, the patient must then choose a treatment course. She can return to a continuous combined hormonal contraceptive, as described above. If she is not able to tolerate continuous combination hormonal or progesterone only therapy, then long-term utilization of a GnRH agonist with add-back can be prescribed (see below). A baseline bone density assessment is obtained after the initial six to nine months of therapy and is then repeated every two years. If bone density remains stable, then the assessment is repeated every two years while the patient is receiving GnRH agonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Add-back therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utilization of add-back therapy can help alleviate the side effects of GnRH agonists without reducing their efficacy, as long as the add-back regimen does not involve high doses of estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/67\">",
"     67",
"    </a>",
"    ]. Add-back therapy is based upon the \"estrogen threshold hypothesis,\" which is demonstrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef53148 \" href=\"UTD.htm?30/25/31134\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/68\">",
"     68",
"    </a>",
"    ]. Basically, adequate sex steroid (estrogen plus progestin, or progestin alone) is provided to prevent significant bone demineralization, but not enough to stimulate growth of endometriotic tissue.",
"   </p>",
"   <p>",
"    Options for sex steroid add-back therapy used in adult women include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       Norethindrone acetate",
"      </a>",
"      (5 mg daily) alone, or",
"     </li>",
"     <li>",
"      Conjugated estrogen (0.625 mg) plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone acetate",
"      </a>",
"      (5 mg) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (5 mg daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patient satisfaction is higher with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    compared with the other options (",
"    <a class=\"graphic graphic_table graphicRef58788 \" href=\"UTD.htm?43/31/44539\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of long-term use of a GnRH agonist with add-back therapy in adolescents is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/57\">",
"     57",
"    </a>",
"    ]. One study performed serial bone mineral density examinations in 36 adolescents receiving a GnRH agonist with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    add-back [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/71\">",
"     71",
"    </a>",
"    ]. Bone density was preserved with this treatment over an 11-month mean treatment period, but preservation of bone density was better at the hip than at the spine. At the hip, 6 subjects had a BMD Z-score between -1.0 and -2.0 SD, while 2 had a Z-score &le;-2.0 SD. At the spine, 11 subjects had a BMD Z-score between -1.0 and -2.0 SD, while 3 had a Z-score &le;-2.0 SD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Danazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    is a 17-alpha-ethinyltestosterone derivative that creates an acyclic environment. Its mechanisms of action include inhibition of pituitary gonadotropin secretion, direct inhibition of endometriotic implant growth, and direct inhibition of ovarian enzymes responsible for estrogen production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of endometriosis\", section on 'Danazol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    's efficacy in treating mild to moderate endometriosis is equivalent to that of a variety of GnRH agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/72-78\">",
"     72-78",
"    </a>",
"    ]. Over 80 percent of patients experience relief or improvement of pain symptoms within two months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/79\">",
"     79",
"    </a>",
"    ]. Large endometriotic cysts and adhesions do not respond well; surgery is the preferred therapy for these lesions.",
"   </p>",
"   <p>",
"    Most women taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    have side effects that are dose-dependent. Side effects include weight gain, muscle cramps, decreased breast size, acne, hirsutism, oily skin, decreased high density lipoprotein levels, irreversible deepening of the voice, increased liver enzymes, hot flashes, mood changes, and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/80\">",
"     80",
"    </a>",
"    ]. Androgenic side effects are related to decreased sex-hormone-binding-globulin levels, resulting in an increase of free testosterone.",
"   </p>",
"   <p>",
"    Bothersome to intolerable side effects are a common reason for discontinuation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/80\">",
"     80",
"    </a>",
"    ]. Although GnRH agonists are also associated with side effects, patients using these drugs report a better quality of life than those taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/81\">",
"     81",
"    </a>",
"    ]. Given the side effect profile, danazol would likely be poorly tolerated by adolescents, and thus is not utilized in the management of endometriosis in the adolescent population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs are helpful adjuvant agents for the treatment of pelvic pain associated with endometriosis. In animal models of surgically induced",
"    <span class=\"nowrap\">",
"     abdominal/peritoneal",
"    </span>",
"    endometriosis, NSAIDs differentially inhibited lesion establishment and growth, resulting in significantly reduced disease burden [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. This effect may also occur in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Nonsteroidal therapies, such as antiinflammatory and antiangiogenic drugs, are an emerging area of investigation in treatment of endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the treatment of endometriosis\", section on 'Analgesics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF RECURRENT PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriosis is a chronic and progressive disease, thus pain can recur despite therapy. Management options for recurrent pain include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changing to a different treatment modality. If girls less than 16 years of age have persistent pain while taking continuous combination hormonal therapy, then utilization of GnRH agonists with add-back therapy may be needed. One course of six to nine months of therapy may be adequate, followed by return to combination continuous hormonal therapy.",
"     </li>",
"     <li>",
"      Prolonged utilization of a GnRH agonist with add-back therapy. We have treated patients with surgically diagnosed disease refractory to other medications with prolonged GnRH agonist treatment plus add-back for over 10 years. A baseline bone density evaluation should be obtained prior to starting retreatment with a GnRH agonist or if therapy is to be continued for over six to nine months.",
"      <br/>",
"      <br/>",
"      We obtain a baseline bone mineral density assessment after the initial six months of therapy and then repeat it two years later. If bone density is stable on GnRH agonist with add-back therapy, then the test is repeated every two years as long as the patient continues on this regimen. If bone density is decreasing despite add-back therapy, then either surgical",
"      <span class=\"nowrap\">",
"       ablation/excision",
"      </span>",
"      or continuous combination hormonal therapy are options. As noted above, the long-term utilization of a GnRH agonist with add-back therapy has not been studied in the adolescent population [",
"      <a class=\"abstract\" href=\"UTD.htm?11/8/11402/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain that does not respond to aggressive medical therapy may be due to recurrent endometriosis, endometriomas,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pelvic adhesions from endometriosis or prior surgery. A repeat laparoscopic procedure should be considered in this clinical situation. If surgery is to be undertaken, then lysis of adhesions should be performed laparoscopically. All visible lesions of endometriosis should be cauterized, laser ablated, or resected. We utilize adhesion preventive agents laparoscopically following surgical lysis of adhesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=see_link\">",
"     \"Preventing postoperative peritoneal adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multi-disciplinary approach to pelvic pain, with the assistance of pain treatment services and complementary and alternative therapies, is also helpful for some adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"       \"Patient information: Endometriosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there is adolescent endometriosis specific downloadable information handouts at",
"    <a class=\"external\" href=\"file://www.youngwomenshealth.org/\">",
"     www.youngwomenshealth.org",
"    </a>",
"    listed below:",
"   </p>",
"   <p>",
"    Endometriosis:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.youngwomenshealth.org/endoinfo.html\">",
"     file://www.youngwomenshealth.org/endoinfo.html",
"    </a>",
"   </p>",
"   <p>",
"    Continuous Hormonal Treatment for Endometriosis:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.youngwomenshealth.org/endo_cont_horm.html\">",
"     file://www.youngwomenshealth.org/endo_cont_horm.html",
"    </a>",
"   </p>",
"   <p>",
"    Hormonal Treatment Options for Adolescent Endometriosis:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.youngwomenshealth.org/hormone-therapy.html\">",
"     file://www.youngwomenshealth.org/hormone-therapy.html",
"    </a>",
"   </p>",
"   <p>",
"    Monthly Live Monitored Chat Rooms for Adolescent with Endometriosis:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.youngwomenshealth.org/chat.html\">",
"     file://www.youngwomenshealth.org/chat.html",
"    </a>",
"   </p>",
"   <p>",
"    Parents Guide to Adolescent Endometriosis:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.youngwomenshealth.org/endo_parent.html\">",
"     file://www.youngwomenshealth.org/endo_parent.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy are to relieve pain, prevent disease progression, and preserve fertility. An algorithm for evaluation and management of adolescents with chronic pelvic pain is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef55370 \" href=\"UTD.htm?10/49/11025\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic endometriosis occurs in adolescents, in rare cases before menarche. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adolescents with endometriosis usually have both acyclic and cyclic pain. Bowel symptoms (eg, rectal pain, constipation, painful defecation that may be cyclic, rectal bleeding) and bladder symptoms (eg, dysuria, urgency, hematuria) are also common, but uterosacral nodularity and ovarian endometriomas are rare. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For evaluation of pelvic pain in adolescents, we suggest history and physical examination, pain diary, laboratory evaluation (eg, pregnancy test, complete blood count, erythrocyte sedimentation rate, urinalysis, urine culture, testing for gonorrhea and chlamydia), and ultrasonography to exclude other anatomic causes. However, a bimanual pelvic examination should not be considered a requirement for evaluation of adolescent pelvic pain. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the pain evaluation suggests a nonacute gynecological source, we suggest medical treatment of",
"      <span class=\"nowrap\">",
"       dysmenorrhea/endometriosis",
"      </span>",
"      rather than laparoscopy for diagnosis and therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest nonsteroidal anti-inflammatory agents and cyclic hormonal therapy for first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Trial of medical therapy for dysmenorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who do not respond to medical therapy within three months should undergo laparoscopy to make a definitive diagnosis and undergo",
"      <span class=\"nowrap\">",
"       ablation/resection",
"      </span>",
"      of lesions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      adhesions. Fifty to 70 percent of adolescents with chronic pelvic pain have endometriosis diagnosed at the time of laparoscopy. A gynecologist familiar with the appearance and treatment of endometriosis in adolescents should perform the surgical laparoscopic procedure. The laparoscopic appearance of endometriosis may be subtle, with red flame lesions and clear shiny peritoneal vesicles rather than powder burns. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Patients who fail therapy for dysmenorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For medical management of confirmed endometriosis in adolescents &le;16 years of age, we suggest continuous hormonal therapy with either a combination",
"      <span class=\"nowrap\">",
"       estrogen/progestin",
"      </span>",
"      or progestin therapy alone for first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Gonadotropin-releasing hormone agonists (with add-back therapy) are a second-line approach. For adolescents &gt;16 years of age, we suggest either continuous combined hormonal contraception or gonadotropin-releasing hormone agonists with add-back therapy as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link\">",
"       \"Overview of the treatment of endometriosis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H18\">",
"       'Postoperative medical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upon completion of GnRH agonist with add-back therapy for six to nine months, the patient begins a continuous combined hormonal contraceptive. If she is not able to tolerate continuous combination hormonal therapy, then we suggest long-term utilization of a GnRH agonist with add-back (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'GnRH agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We have treated patients with surgically diagnosed disease refractory to other medications with prolonged GnRH agonist treatment plus add-back for over 10 years. A baseline bone density evaluation should be obtained prior to starting retreatment with a GnRH agonist or if therapy is to be continued for over six months. If the patient remains on GnRH agonist with add-back therapy, a bone density test should be obtained every two years. Pain that does not respond to aggressive medical therapy may be due to recurrent endometriosis, endometriomas, pelvic adhesions from endometriosis or prior surgery, or a new and different disease process. A repeat laparoscopic procedure should be considered for diagnosis and therapy in this clinical situation. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Management of recurrent pain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/1\">",
"      Vercellini P, Fedele L, Arcaini L, et al. Laparoscopy in the diagnosis of chronic pelvic pain in adolescent women. J Reprod Med 1989; 34:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/2\">",
"      Kontoravdis A, Hassan E, Hassiakos D, et al. Laparoscopic evaluation and management of chronic pelvic pain during adolescence. Clin Exp Obstet Gynecol 1999; 26:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/3\">",
"      Goldstein DP, De Cholnoky C, Emans SJ. Adolescent endometriosis. J Adolesc Health Care 1980; 1:37.",
"     </a>",
"    </li>",
"    <li>",
"     Laufer MR. Gynecologic Pain: Dysmenorrhea, Acute and Chronic Pelvic Pain, Endometriosis, and Premenstrual Syndrome. In: Pediatric &amp; Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Wolters Kluwer Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.238.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/5\">",
"      Reese KA, Reddy S, Rock JA. Endometriosis in an adolescent population: the Emory experience. J Pediatr Adolesc Gynecol 1996; 9:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/6\">",
"      Laufer MR, Goitein L, Bush M, et al. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/7\">",
"      Ballweg ML. Big picture of endometriosis helps provide guidance on approach to teens: comparative historical data show endo starting younger, is more severe. J Pediatr Adolesc Gynecol 2003; 16:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/8\">",
"      Laufer, MR. Premenarcheal endometriosis without an associated obstructive anomaly: Presentation, diagnosis, and treatment. Fertil Steril 2000; 74:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/9\">",
"      Goldstein DP, deCholnoky C, Leventhal JM, Emans SJ. New insights into the old problem of chronic pelvic pain. J Pediatr Surg 1979; 14:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/10\">",
"      Yamamoto K, Mitsuhashi Y, Takaike T, et al. Tubal endometriosis diagnosed within one month after menarche: a case report. Tohoku J Exp Med 1997; 181:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/11\">",
"      Simpson JL, Elias S, Malinak LR, Buttram VC Jr. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol 1980; 137:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/12\">",
"      Sampson, JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 1927; 14:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/13\">",
"      Schifrin BS, Erez S, Moore JG. Teen-age endometriosis. Am J Obstet Gynecol 1973; 116:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/14\">",
"      Sanfilippo JS, Wakim NG, Schikler KN, Yussman MA. Endometriosis in association with uterine anomaly. Am J Obstet Gynecol 1986; 154:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/15\">",
"      Halban, J. Hysteroadenosis metastica. Wien Klin Wochenschr 1924; 37:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/16\">",
"      Meyer, R. Uber entzundliche neterope epithelwucherungen im weiblichen Genetalg ebiet und uber eine bis in die Wurzel des Mesocolon ausgedehnte benigne Wucherung des Dar mepithel. Virch Arch Pathol Anat 1909; 195:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/17\">",
"      Marsh EE, Laufer MR. Endometriosis in premenarcheal girls who do not have an associated obstructive anomaly. Fertil Steril 2005; 83:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/18\">",
"      Batt RE, Mitwally MF. Endometriosis from thelarche to midteens: pathogenesis and prognosis, prevention and pedagogy. J Pediatr Adolesc Gynecol 2003; 16:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/19\">",
"      Gleicher N, el-Roeiy A, Confino E, Friberg J. Is endometriosis an autoimmune disease? Obstet Gynecol 1987; 70:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/20\">",
"      Dmowski WP, Braun D, Gebel H. Endometriosis: genetic and immunologic aspects. Prog Clin Biol Res 1990; 323:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/21\">",
"      Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril 2001; 76:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/22\">",
"      Doyle JO, Missmer SA, Laufer MR. The effect of combined surgical-medical intervention on the progression of endometriosis in an adolescent and young adult population. J Pediatr Adolesc Gynecol 2009; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/23\">",
"      Walling MK, Reiter RC, O'Hara MW, et al. Abuse history and chronic pain in women: I. Prevalences of sexual abuse and physical abuse. Obstet Gynecol 1994; 84:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/24\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Number 310, April 2005. Endometriosis in adolescents. Obstet Gynecol 2005; 105:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/25\">",
"      Wright KN, Laufer MR. Endometriomas in adolescents. Fertil Steril 2010; 94:1529.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/26\">",
"      Cramer DW, Hornstein MD, Ng WG, Barbieri RL. Endometriosis associated with the N314D mutation of galactose-1-phosphate uridyl transferase (GALT). Mol Hum Reprod 1996; 2:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/27\">",
"      Hornstein MD, Thomas PP, Sober AJ, et al. Association between endometriosis, dysplastic naevi and history of melanoma in women of reproductive age. Hum Reprod 1997; 12:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/28\">",
"      Woodworth SH, Singh M, Yussman MA, et al. A prospective study on the association between red hair color and endometriosis in infertile patients. Fertil Steril 1995; 64:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/29\">",
"      Pittaway DE, Fayez JA. The use of CA-125 in the diagnosis and management of endometriosis. Fertil Steril 1986; 46:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/30\">",
"      Stratton P, Winkel C, Premkumar A, et al. Diagnostic accuracy of laparoscopy, magnetic resonance imaging, and histopathologic examination for the detection of endometriosis. Fertil Steril 2003; 79:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/31\">",
"      Tanaka YO, Itai Y, Anno I, et al. MR staging of pelvic endometriosis: role of fat-suppression T1-weighted images. Radiat Med 1996; 14:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/32\">",
"      Ha HK, Lim YT, Kim HS, et al. Diagnosis of pelvic endometriosis: fat-suppressed T1-weighted vs conventional MR images. AJR Am J Roentgenol 1994; 163:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/33\">",
"      Kistner, RW. Treatment of endometriosis by inducing pseudo-pregnancy with ovarian hormones. Fertil Steril 1959; 10:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/34\">",
"      Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/35\">",
"      Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001; 98:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/36\">",
"      Gambone JC, Mittman BS, Munro MG, et al. Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Fertil Steril 2002; 78:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/37\">",
"      Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol 1999; 93:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/38\">",
"      Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/39\">",
"      Propst AM, Laufer MR. Endometriosis in adolescents. Incidence, diagnosis and treatment. J Reprod Med 1999; 44:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/40\">",
"      Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model. J Clin Invest 1994; 93:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/41\">",
"      Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/42\">",
"      Davis GD, Thillet E, Lindemann J. Clinical characteristics of adolescent endometriosis. J Adolesc Health 1993; 14:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/43\">",
"      Demco L. Mapping the source and character of pain due to endometriosis by patient-assisted laparoscopy. J Am Assoc Gynecol Laparosc 1998; 5:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/44\">",
"      Laufer MR. Identification of clear vesicular lesions of atypical endometriosis: a new technique. Fertil Steril 1997; 68:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/45\">",
"      Redwine DB, Yocom LB. A serial section study of visually normal pelvic peritoneum in patients with endometriosis. Fertil Steril 1990; 54:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/46\">",
"      Nisolle M, Paindaveine B, Bourdon A, et al. Histologic study of peritoneal endometriosis in infertile women. Fertil Steril 1990; 53:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/47\">",
"      Fedele L, Parazzini F, Bianchi S, et al. Stage and localization of pelvic endometriosis and pain. Fertil Steril 1990; 53:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/48\">",
"      Sutton CJ, Ewen SP, Whitelaw N, Haines P. Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril 1994; 62:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/49\">",
"      Abbott J, Hawe J, Hunter D, et al. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril 2004; 82:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/50\">",
"      Cook AS, Rock JA. The role of laparoscopy in the treatment of endometriosis. Fertil Steril 1991; 55:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/51\">",
"      Wright J, Lotfallah H, Jones K, Lovell D. A randomized trial of excision versus ablation for mild endometriosis. Fertil Steril 2005; 83:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/52\">",
"      Redwine DB. Conservative laparoscopic excision of endometriosis by sharp dissection: life table analysis of reoperation and persistent or recurrent disease. Fertil Steril 1991; 56:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/53\">",
"      Sutton CJ, Pooley AS, Ewen SP, Haines P. Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis. Fertil Steril 1997; 68:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/54\">",
"      Unger CA, Laufer MR. Progression of endometriosis in non-medically managed adolescents: a case series. J Pediatr Adolesc Gynecol 2011; 24:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/55\">",
"      Yeung P Jr, Sinervo K, Winer W, Albee RB Jr. Complete laparoscopic excision of endometriosis in teenagers: is postoperative hormonal suppression necessary? Fertil Steril 2011; 95:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/56\">",
"      Practice Committee of American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis. Fertil Steril 2008; 90:S260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/57\">",
"      Lubianca JN, Gordon CM, Laufer MR. \"Add-back\" therapy for endometriosis in adolescents. J Reprod Med 1998; 43:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/58\">",
"      Luciano AA, Turksoy RN, Carleo J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 1988; 72:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/59\">",
"      Moghissi KS, Boyce CR. Management of endometriosis with oral medroxyprogesterone acetate. Obstet Gynecol 1976; 47:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/60\">",
"      Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996; 175:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/61\">",
"      Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997; 68:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/62\">",
"      Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009; 79:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/63\">",
"      Ponpuckdee J, Taneepanichskul S. The effects of implanon in the symptomatic treatment of endometriosis. J Med Assoc Thai 2005; 88 Suppl 2:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/64\">",
"      Al-Jefout M, Palmer J, Fraser IS. Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis. Aust N Z J Obstet Gynaecol 2007; 47:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/65\">",
"      Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Health Care 2005; 31:67.",
"     </a>",
"    </li>",
"    <li>",
"     Barbieri RL. Treatment of endometriosis with the GnRH agonists. In: Gonadotropin Releasing Hormone Analogs: Applications in Gynecology, Barbieri RL, Friedman AJ (Eds), Elsevier Science, New York 1991. p.63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/67\">",
"      Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998; 91:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/68\">",
"      Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/69\">",
"      Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002; 99:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/70\">",
"      Kiesel L, Schweppe KW, Sillem M, Siebzehnr&uuml;bl E. Should add-back therapy for endometriosis be deferred for optimal results? Br J Obstet Gynaecol 1996; 103 Suppl 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/71\">",
"      Divasta AD, Laufer MR, Gordon CM. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis. J Pediatr Adolesc Gynecol 2007; 20:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/72\">",
"      Kennedy SH, Williams IA, Brodribb J, et al. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 1990; 53:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/73\">",
"      Wheeler JM, Knittle JD, Miller JD. Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. Am J Obstet Gynecol 1993; 169:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/74\">",
"      Rock JA, Truglia JA, Caplan RJ. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group. Obstet Gynecol 1993; 82:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/75\">",
"      Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET). Fertil Steril 1992; 57:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/76\">",
"      Crosignani PG, Gastaldi A, Lombardi PL, et al. Leuprorelin acetate depot vs danazol in the treatment of endometriosis: results of an open multicentre trial. Clin Ther 1992; 14 Suppl A:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/77\">",
"      Shaw RW. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team. Fertil Steril 1992; 58:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/78\">",
"      Shaw RW. Nafarelin in the treatment of pelvic pain caused by endometriosis. Am J Obstet Gynecol 1990; 162:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/79\">",
"      Barbieri RL, Evans S, Kistner RW. Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril 1982; 37:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/80\">",
"      Buttram VC Jr, Reiter RC, Ward S. Treatment of endometriosis with danazol: report of a 6-year prospective study. Fertil Steril 1985; 43:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/81\">",
"      Burry KA. Nafarelin in the management of endometriosis: quality of life assessment. Am J Obstet Gynecol 1992; 166:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/82\">",
"      Efstathiou JA, Sampson DA, Levine Z, et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 2005; 83:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/83\">",
"      Ozawa Y, Murakami T, Tamura M, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice. Fertil Steril 2006; 86:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/84\">",
"      Olivares C, Bilotas M, Buquet R, et al. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod 2008; 23:2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/85\">",
"      Laschke MW, Elitzsch A, Scheuer C, et al. Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril 2007; 87:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/8/11402/abstract/86\">",
"      Kyama CM, Mihalyi A, Simsa P, et al. Non-steroidal targets in the diagnosis and treatment of endometriosis. Curr Med Chem 2008; 15:1006.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7415 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-CC27B9A4A4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11402=[""].join("\n");
var outline_f11_8_11402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TRIAL OF MEDICAL THERAPY FOR DYSMENORRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NSAIDs and hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gonadotropin releasing hormone agonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PATIENTS WHO FAIL THERAPY FOR DYSMENORRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnostic (and therapeutic) laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POSTOPERATIVE MEDICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Continuous hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6499963\">",
"      - Combination estrogen/progestins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Progestins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      GnRH agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Add-back therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Danazol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nonsteroidal antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MANAGEMENT OF RECURRENT PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7415\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7415|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/34/17954\" title=\"figure 1\">",
"      Classification of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/25/31134\" title=\"figure 2\">",
"      Estrogen treshold hypothesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/49/11025\" title=\"figure 3\">",
"      Algorithm eval rx CPP adol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7415|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/18/24868\" title=\"picture 1\">",
"      Endometriosis implants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7415|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/38/8811\" title=\"table 1\">",
"      Sxs adolescent endometriosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/42/21163\" title=\"table 2\">",
"      Initial hx endometriosis adoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/48/13069\" title=\"table 3\">",
"      Causes of an elevated CA 125",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/52/29516\" title=\"table 4\">",
"      NSAID dose for medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/46/1771\" title=\"table 5\">",
"      Types of endometriosis lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/25/2459\" title=\"table 6\">",
"      Endometriosis pain by stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/31/44539\" title=\"table 7\">",
"      GnRH add back regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=related_link\">",
"      Contraception: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=related_link\">",
"      Evaluation of the child and adolescent with chronic abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8761?source=related_link\">",
"      Gonadotropin releasing hormone agonists for long-term treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=related_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=related_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=related_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=related_link\">",
"      Preventing postoperative peritoneal adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31125?source=related_link\">",
"      Primary dysmenorrhea in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=related_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=related_link\">",
"      Thoracic endometriosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_8_11403="Mast cell mediated angioedema";
var content_f11_8_11403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F58834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F58834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of mast cell-mediated angioedema",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       IgE-dependent allergic reactions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Foods",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Drugs (antibiotics, local anesthetics, hormones)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stinging insects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Latex",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Contact (fresh fruits and vegetables, animal saliva)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Direct mast cell mediator release",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Opiates",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muscle relaxants (succinylcholine, curare)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiocontrast agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Perturbations in arachidonic acid metabolism within mast cells",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11403=[""].join("\n");
var outline_f11_8_11403=null;
var title_f11_8_11404="Comparison of esophageal motility findings";
var content_f11_8_11404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of esophageal motility findings using conventional manometry and high resolution manometry",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Conventional manometry",
"       </td>",
"       <td class=\"subtitle1\">",
"        High resolution manometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Velocity",
"       </td>",
"       <td>",
"        &lt;8 cm/sec (8 to 3 cm above LES)",
"       </td>",
"       <td>",
"        &lt;8 cm/sec CFV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amplitude",
"       </td>",
"       <td>",
"        DEA &lt;220 mmHg",
"       </td>",
"       <td>",
"        DCI &lt;5000 mmHg&bull;cm&bull;sec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LESP",
"       </td>",
"       <td>",
"        10 to 45 mmHg",
"       </td>",
"       <td>",
"        10 to 35 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LESR",
"       </td>",
"       <td>",
"        &lt;8 mmHg",
"       </td>",
"       <td>",
"        &lt;15 mmHg (4-second IRP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Diffuse esophageal spasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Velocity",
"       </td>",
"       <td>",
"        &gt;8 cm/sec",
"       </td>",
"       <td>",
"        CFV &gt;8 cm/sec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Nutcracker esophagus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amplitude",
"       </td>",
"       <td>",
"        DEA &gt;220 mmHg",
"       </td>",
"       <td>",
"        <p>",
"         DCI &gt;5000 mmHg&bull;cm&bull;sec",
"        </p>",
"        <p>",
"         \"Spastic nutcracker\", DCI &gt;8000 mmHg&bull;cm&bull;sec",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Hypertensive lower esophageal sphincter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LESP",
"       </td>",
"       <td>",
"        &gt;45 mmHg",
"       </td>",
"       <td>",
"        &gt;35 mmHg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LES: lower esophageal sphincter; LESP: lower esophageal sphincter pressure; CFV: contractile front velocity; DEA: distal esophageal amplitude; DCI: distal contractile integral; IRP: integrated relaxation pressure; LESR: lower esophageal sphincter relaxation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11404=[""].join("\n");
var outline_f11_8_11404=null;
var title_f11_8_11405="DDx TPLL path";
var content_f11_8_11405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of T cell prolymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Entity",
"      </td>",
"      <td class=\"subtitle1\">",
"       Histology",
"      </td>",
"      <td class=\"subtitle1\">",
"       Immunophenotype",
"      </td>",
"      <td class=\"subtitle1\">",
"       Genetic features/Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T cell prolymphocytic leukemia (T-PLL)",
"      </td>",
"      <td>",
"       Typically, tumor cells are \"prolymphocytes\" of medium size with moderately condensed chromatin and a visible nucleolus. Round or oval nucleus with moderately abundant agranular cytoplasm. Cytoplasmic protrusions (blebs) are common. Small cell and cerebriform variants can be seen.",
"      </td>",
"      <td>",
"       <p>",
"        Express CD52 (strongly) and pan-T cell markers (CD2, CD3, and CD7). TdT is negative. Expression of CD4 and CD8 is variable.",
"       </p>",
"       <p>",
"        TCL1 can be demonstrated by immunohistochemistry.",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        inv(14q), t(14;14)(q11;q32), or t(X;14)(q28;q11)",
"       </p>",
"       <p>",
"        TCR genes are clonally rearranged.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B cell prolymphocytic leukemia",
"      </td>",
"      <td>",
"       <p>",
"        &gt;55 percent (and usually &gt;90 percent) of circulating white cells are \"prolymphocytes\".",
"       </p>",
"       <p>",
"        The bone marrow is infiltrated in an interstitial or nodular pattern by similar cells.",
"       </p>",
"      </td>",
"      <td>",
"       Express bright surface IgM +/- IgD and bright CD20 as well as other B-cell antigens (CD19, CD22, CD79a, FMC7).",
"      </td>",
"      <td>",
"       <p>",
"        t(11;14) must be excluded.",
"       </p>",
"       <p>",
"        No associated paraproteinemia.",
"       </p>",
"       <p>",
"        TCR genes are",
"        <strong>",
"         not",
"        </strong>",
"        clonally rearranged.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL)",
"      </td>",
"      <td>",
"       <p>",
"        \"Typical\" CLL cells are small mature appearing lymphocytes with a dense nucleus, partially aggregated chromatin, no discernible nucleoli, and a narrow border of cytoplasm.",
"       </p>",
"       <p>",
"        A minority of cells may have a prolymphocytic morphology.",
"       </p>",
"      </td>",
"      <td>",
"       Typically express B-cell antigens (CD19, CD22, CD79a, FMC7); CD5; and CD23. Expression of CD20 and surface immunoglobulin is dim.",
"      </td>",
"      <td>",
"       <p>",
"        Trisomy 12, deletions of 6q, 11q, 13q, and 17p",
"       </p>",
"       <p>",
"        TCR genes are",
"        <strong>",
"         not",
"        </strong>",
"        clonally rearranged.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycosis fungoides (MF)",
"      </td>",
"      <td>",
"       Small to medium-sized atypical mononuclear cells with cerebriform nuclei (Sezary cells). Variant of T-PLL has cerebriform morphology similar to that of MF.",
"      </td>",
"      <td>",
"       Typically lack one or more of the following: CD2, CD3, CD5, and CD7.",
"      </td>",
"      <td>",
"       <p>",
"        TCR genes are clonally rearranged.",
"       </p>",
"       <p>",
"        Diagnosis uses an algorithm incorporating clinical data.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adult T cell lymphoma/leukemia",
"      </td>",
"      <td>",
"       Tumor morphology is variable, but often demonstrates medium-sized lymphocytes with condensed chromatin and bizarre hyperlobated nuclei (\"clover leaf\" or \"flower\" cells).",
"      </td>",
"      <td>",
"       Express pan-T cell antigens (CD2, CD4, CD5), typically lack CD7, and may have dim expression of CD3.",
"      </td>",
"      <td>",
"       <p>",
"        Positive serology or PCR for the human T-lymphotropic virus, type I (HTLV-I).",
"       </p>",
"       <p>",
"        TCR genes are clonally rearranged.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T cell large granular lymphocyte leukemia",
"      </td>",
"      <td>",
"       Large lymphoid cells with abundant cytoplasm containing typical azurophilic granules with a reniform or round nucleus.",
"      </td>",
"      <td>",
"       Express pan-T cell antigens (CD2, CD3, CD5, CD7). Express CD8 and CD57. CD16 and CD56 expression is variable.",
"      </td>",
"      <td>",
"       TCR genes are clonally rearranged.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hairy cell leukemia",
"      </td>",
"      <td>",
"       Variant has circulating tumor cells with morphology intermediate between hairy cells and prolymphocytes.",
"      </td>",
"      <td>",
"       Strongly express pan-B cell antigens (CD19, CD20, CD22), and usually lack expression of CD5, CD10, CD21, and CD23. Characteristically express CD11c, CD25, CD103, CD123, cyclin D1, and annexin A1.",
"      </td>",
"      <td>",
"       TCR genes are",
"       <strong>",
"        not",
"       </strong>",
"       clonally rearranged.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCR: polymerase chain reaction; TdT: terminal deoxynucleotidyl transferase; TCL1: T cell leukemia 1; TCR: T cell receptor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11405=[""].join("\n");
var outline_f11_8_11405=null;
var title_f11_8_11406="Contents: Cystic disease";
var content_f11_8_11406=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/41/670\">",
"       Nephrology and Hypertension",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cystic disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cystic disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acquired cystic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23638\">",
"           Acquired cystic disease of the kidney in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medullary cystic kidney disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/59/33721\">",
"           Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/56/10120\">",
"           Genetics and pathogenesis of nephronophthisis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polycystic kidney disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28584\">",
"           Autosomal dominant polycystic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/13/29913\">",
"           Autosomal recessive polycystic kidney disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/27/27066\">",
"           Course and treatment of autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/13/9433\">",
"           Diagnosis of and screening for autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/33/30233\">",
"           Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34009\">",
"           Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30582\">",
"           Hypertension in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/11/37048\">",
"           Pain syndromes in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/24/38277\">",
"           Patient information: Polycystic kidney disease (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/11/30903\">",
"           Renal manifestations of autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/44/4807\">",
"           Urinary tract infection in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Simple and complex renal cysts",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/3/27704\">",
"           Simple and complex renal cysts in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tuberous sclerosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/18/43303\">",
"           Renal manifestations of tuberous sclerosis and renal angiomyolipoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/38/34410\">",
"           Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32328\">",
"           Tuberous sclerosis complex: Management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         von Hippel-Lindau disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22618\">",
"           Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/21/14678\">",
"           Molecular biology and pathogenesis of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-09EAAFA73C-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f11_8_11406=[""].join("\n");
var outline_f11_8_11406=null;
var title_f11_8_11407="Recommended initial doses oral drugs for chronic pain in elderly";
var content_f11_8_11407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F83201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F83201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AGS recommended initial doses for oral drugs used for persistent pain in the elderly",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"16%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"26%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        US trade name(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic equivalent available in US",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested initial dose",
"        <br/>",
"        (oral administration)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Selected characteristics relevant to older patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Nonopioid analgesic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetaminophen (paracetamol)",
"       </td>",
"       <td>",
"        Tylenol, Mapap (others)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        325 to 500 mg every four hours or 500 to 1000 mg every six hours (maximum 3 g per day)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Often acetaminophen is the analgesic of choice for older adults. Its clearance is reduced with aging; maximum 3 g per day suggested for frail older individuals or those with organ dysfunction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celecoxib",
"       </td>",
"       <td>",
"        Celebrex",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        100 mg daily",
"       </td>",
"       <td>",
"        Patients with indications for cardioprotection require aspirin supplement; therefore, older individuals will still require concurrent gastroprotection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ibuprofen",
"       </td>",
"       <td>",
"        Advil, Motrin",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        200 mg three times daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nabumetone",
"       </td>",
"       <td>",
"        Relafen",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        1 g daily or 500 mg twice daily",
"       </td>",
"       <td>",
"        Minimal antiplatelet effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Naproxen sodium",
"       </td>",
"       <td>",
"        Aleve, Anaprox, Naprelan, Naprosyn",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        220 mg (equivalent to 200 mg naproxen base) twice daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choline magnesium trisalicylate",
"       </td>",
"       <td>",
"        Trilisate (US brand no longer available)",
"       </td>",
"       <td>",
"        Yes (limited availability)",
"       </td>",
"       <td>",
"        500 to 750 mg every eight hours",
"       </td>",
"       <td>",
"        Minimal antiplatelet effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Magnesium salicylate",
"       </td>",
"       <td>",
"        Doan's, Keygesic",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        580 mg (equivalent to 467.2 mg) every six hours as needed",
"       </td>",
"       <td>",
"        Minimal antiplatelet effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diclofenac",
"       </td>",
"       <td>",
"        Voltaren, Cataflam",
"       </td>",
"       <td>",
"        Yes (tablets)",
"       </td>",
"       <td>",
"        50 mg twice daily or 75 mg delayed release daily",
"       </td>",
"       <td>",
"        May be associated with higher cardiovascular risk compared to other traditional NSAIDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Opioids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydrocodone",
"       </td>",
"       <td>",
"        Lorcet, Lortab, Norco, Vicodin, Vicoprofen",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        2.5 to 5 mg (hydrocodone component) every four to six hours",
"       </td>",
"       <td>",
"        In US, hydrocodone is available ONLY in combinations with acetaminophen or ibuprofen. See Lexicomp reference or licensed prescribing information for detail of acetaminophen or ibuprofen content.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        Hydromorphone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Immediate release",
"       </td>",
"       <td class=\"sublist_other\">",
"        Dilaudid",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 to 2 mg every three to four hours",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Extended release",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Exalgo",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"       <td class=\"sublist_other\">",
"        8 mg daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        Morphine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Immediate release",
"       </td>",
"       <td class=\"sublist_other\">",
"        MSIR (US brand no longer available)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.5 to 10 mg every four hours (oral solution available; lowest tablet strength available is 15 mg)",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"2\">",
"        Active metabolites can accumulate in older persons with renal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sustained release",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Avinza, Kadian, MSContin, Oramorph SR",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes (except sustained release capsule)",
"       </td>",
"       <td class=\"sublist_other\">",
"        15 mg every 8 to 24 hours (dose interval varies by specific preparation; see Lexicomp reference or dosing guidelines in licensed prescribing information for product)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        Oxycodone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Immediate release",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        OxyIR, Oxecta, Roxicodone",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.5 to 5 mg every four to six hours",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"2\">",
"        Reduced clearance in older persons with renal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Controlled release",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Oxycontin",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"       <td class=\"sublist_other\">",
"        10 mg every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        Oxymorphone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Immediate release",
"       </td>",
"       <td class=\"sublist_other\">",
"        Opana IR",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"       <td class=\"sublist_other\">",
"        5 mg every six hours",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Extended release",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Opana ER",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"       <td class=\"sublist_other\">",
"        5 mg every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transdermal fentanyl",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Duragesic",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        12 to 25 mcg/hour patch every 72 hours",
"       </td>",
"       <td>",
"        Steady state levels may not be reached in older adults until patch is used for six to nine days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        Tapentadol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Immediate release",
"       </td>",
"       <td class=\"sublist_other\">",
"        Nucynta",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"       <td class=\"sublist_other\">",
"        50 mg every four to six hours",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"2\">",
"        Combined mu opioid receptor agonist and norepinephrine reuptake inhibitor. 50 mg tapentadol &asymp; 10 mg oxycodone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Extended release",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Nucynta ER",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"       <td class=\"sublist_other\">",
"        50 mg every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Adjuvant agents",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        Serotonin-norepinephrine reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Duloxetine",
"       </td>",
"       <td class=\"sublist_other\">",
"        Cymbalta",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"       <td class=\"sublist_other\">",
"        20 mg daily",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Venlafaxine",
"       </td>",
"       <td class=\"sublist_other\">",
"        Effexor",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"       <td class=\"sublist_other\">",
"        25 mg twice daily (immediate release) or 37.5 mg daily (extended release)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Milnacipran",
"       </td>",
"       <td class=\"sublist_other\">",
"        Savella",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"       <td class=\"sublist_other\">",
"        Start 12.5 mg once daily on day one; titrate over seven days according to Lexicomp reference or licensed prescribing information to final dose 50 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        Tricyclic antidepressants*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Desipramine",
"       </td>",
"       <td class=\"sublist_other\">",
"        Norpramin",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        10 mg at bedtime",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Monitor sedation, hypotension, cardiac and anticholinergic effects. Nortriptyline is preferred in older adults due to lower risk of accumulation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nortriptyline",
"       </td>",
"       <td class=\"sublist_other\">",
"        Pamelor",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Amitriptyline",
"       </td>",
"       <td class=\"sublist_other\">",
"        Elavil",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        Anticonvulsants*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gabapentin",
"       </td>",
"       <td class=\"sublist_other\">",
"        Neurontin",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"       <td class=\"sublist_other\">",
"        100 mg at bedtime",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"2\">",
"        Monitor sedation and ataxia. Reduced clearance in older persons with renal insufficiency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pregabalin",
"       </td>",
"       <td class=\"sublist_other\">",
"        Lyrica",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"       <td class=\"sublist_other\">",
"        50 mg at bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lamotrigine",
"       </td>",
"       <td class=\"sublist_other\">",
"        Lamictal",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes (immediate release tablet)",
"       </td>",
"       <td class=\"sublist_other\">",
"        25 mg at bedtime",
"       </td>",
"       <td class=\"sublist_other\">",
"        Monitor sedation, ataxia and rash",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table shows suggested initial (low) analgesic doses for pharmacologic management of chronic, non-malignant pain in older adults. The choice of specific agent, dose, titration, and use of drug combinations must be individualized. For additional information, see UpToDate topics and Lexicomp drug information reference included with UpToDate.",
"    <div class=\"footnotes\">",
"     NSAIDs: nonsteroidal antiinflammatory drugs.",
"     <br/>",
"     * Lowest starting dose shown should be considered in frail older persons with a history of sensitivity to central nervous system-active drugs, reduced cardiac output, dehydration, low body weight, or poor oral intake.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The maximum dose for over-the-counter acetaminophen is now 3 grams per day due to the often inappropriate use of acetaminophen in combination over-the-counter products by consumers. In highly controlled environments, such as nursing facilities, where it can be assured that the patient is not receiving extra acetaminophen from other combination medications, up to 4 grams can still be used for purposes of analgesia.",
"     <br/>",
"     &Delta; We suggest establishing dose and effects using an immediate release opioid preparation prior to prescribing a sustained release opioid for opioid-na&iuml;ve older patients.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Also available with acetaminophen.",
"     <br/>",
"     &sect; In general, dose tapering is recommended prior to discontinuation of anticonvulsants, opioids and antidepressants.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57:1331.",
"      </li>",
"      <li>",
"       Barber JB, Gibson SJ. Treatment of chronic non-malignant pain in the elderly: safety considerations. Drug Saf 2009; 32:457.",
"      </li>",
"      <li>",
"       Gianni W, Ceci M, Bustacchini S, et al. Opioids for the treatment of chronic non-cancer pain in older people. Drugs Aging 2009; 26 Suppl 1:63.",
"      </li>",
"      <li>",
"       Fitzcharles MA, Lussier D, Shir Y. Management of chronic arthritis pain in the elderly. Drugs Aging 2010; 27:471.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_8_11407=[""].join("\n");
var outline_f11_8_11407=null;
